

# Appendix 19c: Clinical evidence forest plots for pharmacology and other physical treatments

## Contents

Amitriptyline .....	4
Antidepressants versus TCAs sub-analyses .....	44
Atypical depression sub-analyses.....	70
Augmentation with a benzodiazepine.....	82
Augmentation with buspirone.....	85
Augmentation with pindolol.....	86
Augmentation with triiodothyronine (T3) .....	97
Duloxetine.....	98
Dul.01 to 02. Duloxetine versus placebo - acute phase .....	98
Dul.03 to 04. Duloxetine comparing different doses - acute phase.....	118
Dul.05 to 06. Duloxetine versus other antidepressants - acute phase.....	126
Dul.07. Duloxetine versus placebo - continuation phase for partial responders .....	135
Dul.08. Duloxetine comparing different doses - continuation phase for partial responders .....	137
Dul.09. Duloxetine versus other antidepressants - continuation phase for partial responders.....	139
Dul.10. Duloxetine versus placebo - continuation phase for those achieving remission.....	141
Dul.11. Duloxetine versus other antidepressants - continuation phase for all.....	141
Escitalopram .....	144
Esc.01. Escitalopram versus placebo .....	144
Esc.02. Escitalopram versus all other antidepressants.....	151
Esc.03. Escitalopram versus SSRIs .....	158
Esc.04. Escitalopram versus non-SSRIs.....	168
Esc.05. Escitalopram versus all other antidepressants - citalopram separated .....	175
Esc.06. Escitalopram: overall efficacy - ordered by baseline severity .....	182
Esc.07. Escitalopram: overall acceptability and tolerability - ordered by baseline severity .....	186
Esc.08. Escitalopram: overall efficacy versus active treatment - by comparator drug .....	189
Esc.09. Escitalopram: overall acceptability and tolerability versus active treatment - by comparator drug .....	199
Esc.10. Escitalopram: overall efficacy - by dose .....	205
Esc.11. Escitalopram: overall acceptability and tolerability - by dose .....	209


Low dose TCAs .....	212
Mirtazapine.....	216
Moclobemide .....	262
Next-step treatments .....	302
Next-step 01. Dose escalation .....	302
Next-step switching.....	309
Next-step 02. Switching: continuing antidepressants versus switching.....	309
Next-step 03. Switching: switching to single or combination drugs .....	315
Next-step 04. Switching to a single drug.....	322
Next-step 05. Switching: single antidepressants versus augmentation strategy .....	323
Next-step 06. Switching: single antidepressants (open-label data).....	325
Next-step 07. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) .....	330
Next-step 08. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing).....	336
Next-step 09. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing).....	342
Next-step 10. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug - open-label data .....	347
Next-step 11. Comparisons involving CBT - open-label data.....	352
Next-step 12. Electroconvulsive therapy (ECT).....	356
Older adults sub-analyses.....	365
Phenelzine .....	411
Depression with psychotic features.....	424
Reboxetine.....	434
Relapse prevention .....	443
SSRIs versus antidepressants .....	523
SSRIs versus placebo .....	567
St John's wort.....	583
TCAs versus placebo .....	627
TCA.01. TCAs versus placebo - efficacy data.....	627
TCA.02. TCAs versus placebo - acceptability and tolerability data.....	633
Venlafaxine .....	636
Treatments for depression with a seasonal pattern/seasonal affective disorder (SAD) .....	775
SAD.01. Treatments for SAD - bright light versus waitlist control.....	775
SAD.02. Treatments for SAD - bright light versus attentional control.....	781

SAD.03. Treatments for SAD – bright light versus active treatment control .....	789
SAD.04. Treatments for SAD – bright light versus light + CBT combination .....	794
SAD.05. Treatments for SAD – morning versus afternoon/evening bright light box .....	798
SAD.06. Treatments for SAD – dawn simulation versus attentional control .....	803
SAD.07. Treatments for SAD – bright light versus dawn simulation .....	808
SAD.08. Treatments for SAD – bright light – prevention of new episode.....	811
SAD.09. Treatments for SAD – acute-phase treatment – antidepressants versus placebo (efficacy data) .....	812
SAD.10. Treatments for SAD – acute-phase treatment – antidepressants versus placebo (acceptability and tolerability data) .....	815
SAD.11. Treatments for SAD – acute-phase treatment – antidepressants versus active control (efficacy data) .....	817
SAD.12. Treatments for SAD – overall efficacy (other interventions) .....	818
SAD.13. Treatments for SAD – continuation treatment .....	818
SAD.14. Treatments for SAD – antidepressants – prevention of a new episode .....	819


**Please note that due to the size of some of the forest plots you may need to use the zoom feature to view the data.**

# Amitriptyline


Review: Pharmacology: Amitriptyline  
 Comparison: 01 Overall efficacy  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline  
 Comparison: 01 Overall efficacy  
 Outcome: 02 Mean scores at endpoint




Review: Pharmacology: Amitriptyline  
 Comparison: 01 Overall efficacy  
 Outcome: 03 Number of inpatients not achieving at least 50% reduction in depression score



Review: Pharmacology: Amitriptyline  
 Comparison: 01 Overall efficacy  
 Outcome: 04 Mean scores at endpoint in inpatients




Review: Pharmacology: Amitriptyline  
 Comparison: 01 Overall efficacy  
 Outcome: 05 Number of outpatients not achieving at least 50% reduction in depression score







Review: Pharmacology: Amitriptyline  
 Comparison: 01 Overall efficacy  
 Outcome: 06 Mean scores at endpoint in outpatients




Review: Pharmacology: Amitriptyline  
 Comparison: 01 Overall efficacy  
 Outcome: 07 Number of primary care patients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline  
 Comparison: 01 Overall efficacy  
 Outcome: 08 Mean scores at endpoint in primary care patients







Review: Pharmacology: Amitriptyline  
 Comparison: 02 Overall tolerability  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Amitriptyline  
 Comparison: 02 Overall tolerability  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Amitriptyline  
 Comparison: 02 Overall tolerability  
 Outcome: 04 Inpatients leaving the study early




Review: Pharmacology: Amitriptyline  
 Comparison: 02 Overall tolerability  
 Outcome: 05 Leaving the study early due to side effects in inpatients



Review: Pharmacology: Amitriptyline  
 Comparison: 02 Overall tolerability  
 Outcome: 06 Inpatients reporting side effects




Review: Pharmacology: Amitriptyline  
 Comparison: 02 Overall tolerability  
 Outcome: 07 Outpatients leaving the study early







Review: Pharmacology: Amitriptyline  
 Comparison: 02 Overall tolerability  
 Outcome: 08 Leaving the study early due to side effects in outpatients




Review: Pharmacology: Amitriptyline  
 Comparison: 02 Overall tolerability  
 Outcome: 09 Outpatients reporting side effects




Review: Pharmacology: Amitriptyline  
 Comparison: 02 Overall tolerability  
 Outcome: 10 Primary care patients leaving the study early




Review: Pharmacology: Amitriptyline  
 Comparison: 02 Overall tolerability  
 Outcome: 11 Leaving the study early due to side effects in primary care patients




Review: Pharmacology: Amitriptyline  
 Comparison: 02 Overall tolerability  
 Outcome: 12 Patients in primary care reporting side effects




Review: Pharmacology: Amitriptyline  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 02 Mean scores at endpoint




Review: Pharmacology: Amitriptyline  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 03 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 04 Mean scores at endpoint in inpatients




Review: Pharmacology: Amitriptyline  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 05 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 06 Mean scores at endpoint in outpatients



Review: Pharmacology: Amitriptyline  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 07 Mean scores at endpoint in primary care




Review: Pharmacology: Amitriptyline  
 Comparison: 04 Tolerability against TCAs  
 Outcome: 01 Leaving the study early







Review: Pharmacology: Amitriptyline  
 Comparison: 04 Tolerability against TCAs  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Amitriptyline  
 Comparison: 04 Tolerability against TCAs  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Amitriptyline  
 Comparison: 04 Tolerability against TCAs  
 Outcome: 04 Inpatients leaving the study early




Review: Pharmacology: Amitriptyline  
 Comparison: 04 Tolerability against TCAs  
 Outcome: 05 Leaving the study early due to side effects in inpatients




Review: Pharmacology: Amitriptyline  
 Comparison: 04 Tolerability against TCAs  
 Outcome: 06 Outpatients leaving the study early




Review: Pharmacology: Amitriptyline  
 Comparison: 04 Tolerability against TCAs  
 Outcome: 07 Leaving the study early due to side effects in outpatients




Review: Pharmacology: Amitriptyline  
 Comparison: 04 Tolerability against TCAs  
 Outcome: 08 Outpatients reporting side effects




Review: Pharmacology: Amitriptyline  
 Comparison: 04 Tolerability against TCAs  
 Outcome: 09 Leaving the study early in primary care




Review: Pharmacology: Amitriptyline  
 Comparison: 04 Tolerability against TCAs  
 Outcome: 10 Leaving the study early due to side effects in primary care




Review: Pharmacology: Amitriptyline  
 Comparison: 05 Efficacy against SSRIs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline  
 Comparison: 05 Efficacy against SSRIs  
 Outcome: 02 Mean scores at endpoint



Review: Pharmacology: Amitriptyline  
 Comparison: 05 Efficacy against SSRIs  
 Outcome: 03 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline  
 Comparison: 05 Efficacy against SSRIs  
 Outcome: 04 Mean scores at endpoint in inpatients







Review: Pharmacology: Amitriptyline  
 Comparison: 05 Efficacy against SSRIs  
 Outcome: 05 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline  
 Comparison: 05 Efficacy against SSRIs  
 Outcome: 06 Mean scores at endpoint in outpatients




Review: Pharmacology: Amitriptyline  
 Comparison: 05 Efficacy against SSRIs  
 Outcome: 07 Mean scores at endpoint in primary care patients




Review: Pharmacology: Amitriptyline  
 Comparison: 05 Efficacy against SSRIs  
 Outcome: 08 Number of primary care patients not achieving at least 50% reduction in depression score




Review: Pharmacology: Amitriptyline  
 Comparison: 06 Tolerability against SSRIs  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Amitriptyline  
 Comparison: 06 Tolerability against SSRIs  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Amitriptyline  
 Comparison: 06 Tolerability against SSRIs  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Amitriptyline  
 Comparison: 06 Tolerability against SSRIs  
 Outcome: 04 Inpatients leaving the study early




Review: Pharmacology: Amitriptyline  
 Comparison: 06 Tolerability against SSRIs  
 Outcome: 05 Leaving the study early due to side effects in inpatients



Review: Pharmacology: Amitriptyline  
 Comparison: 06 Tolerability against SSRIs  
 Outcome: 06 Inpatients reporting side effects




Review: Pharmacology: Amitriptyline  
 Comparison: 06 Tolerability against SSRIs  
 Outcome: 07 Outpatients leaving the study early







Review: Pharmacology: Amitriptyline  
 Comparison: 06 Tolerability against SSRIs  
 Outcome: 08 Leaving the study early due to side effects in outpatients




Review: Pharmacology: Amitriptyline  
 Comparison: 06 Tolerability against SSRIs  
 Outcome: 09 Primary care patients leaving the study early



Review: Pharmacology: Amitriptyline  
 Comparison: 06 Tolerability against SSRIs  
 Outcome: 10 Leaving the study early due to side effects in primary care patients




Review: Pharmacology: Amitriptyline  
 Comparison: 06 Tolerability against SSRIs  
 Outcome: 11 Primary care patients reporting side effects




# Antidepressants versus TCAs sub-analyses


Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 02 Sensitivity analysis: Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 03 Number of people not achieving remission




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 04 Sensitivity analysis: Number of people not achieving remission



Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 05 Mean scores at endpoint




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 06 Sensitivity analysis: Mean scores at endpoint







Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 07 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 08 Sensitivity analysis: Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 09 Mean scores at endpoint in inpatients




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 10 Sensitivity analysis: Mean scores at endpoint in inpatients




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 11 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 12 Sensitivity analysis: Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 13 Number of outpatients not achieving remission



Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 14 Sensitivity analysis: Number of outpatients not achieving remission




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 15 Mean scores at endpoint in outpatients







Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 16 Sensitivity analysis: Mean scores at endpoint in outpatients




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 01 TCAs against alternative antidepressants: Efficacy (not TCAs v amitriptyline)  
 Outcome: 17 Mean scores at endpoint in primary care




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)  
 Outcome: 03 Patients reporting side effects



Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)  
 Outcome: 04 Inpatients leaving the study early




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)  
 Outcome: 05 Outpatients leaving the study early




0.1 0.2 0.5 1 2 5 10  
 Favours Control Favours TCAs

Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)  
 Outcome: 06 Primary care patients leaving the study early







Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)  
 Outcome: 07 Inpatients leaving the study early due to side effects




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)  
 Outcome: 08 Outpatients leaving the study early due to side effects




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)  
 Outcome: 09 Primary care patients leaving the study early due to side effects




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)  
 Outcome: 10 Inpatients reporting side effects



Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)  
 Outcome: 11 Outpatients reporting side effects




Review: Pharmacology: Antidepressants versus TCAs  
 Comparison: 03 TCAs against alternative antidepressants: Tolerability (not TCAs v amitriptyline)  
 Outcome: 12 Primary care patients reporting side effects




## Atypical depression sub-analyses


Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 01 Phenelzine v other antidepressants  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 01 Phenelzine v other antidepressants  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 01 Phenelzine v other antidepressants  
 Outcome: 03 Mean end point scores



Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 01 Phenelzine v other antidepressants  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 01 Phenelzine v other antidepressants  
 Outcome: 05 Leaving the study early due to side effects







Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 02 Phenelzine v TCAs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 02 Phenelzine v TCAs  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 02 Phenelzine v TCAs  
 Outcome: 03 Mean end point scores




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 03 Phenelzine v fluoxetine  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 03 Phenelzine v fluoxetine  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 03 Phenelzine v fluoxetine  
 Outcome: 03 Mean end point scores




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 03 Phenelzine v fluoxetine  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 03 Phenelzine v fluoxetine  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 04 Fluoxetine v other antidepressants  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 04 Fluoxetine v other antidepressants  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 04 Fluoxetine v other antidepressants  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 04 Fluoxetine v other antidepressants  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 04 Fluoxetine v other antidepressants  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 05 Fluoxetine v TCAs  
 Outcome: 01 Mean endpoint scores



Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 07 TCAs v other antidepressants  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 07 TCAs v other antidepressants  
 Outcome: 02 Number of people not achieving remission






Review: Pharmacology: Atypical depression sub-analysis  
 Comparison: 07 TCAs v other antidepressants  
 Outcome: 03 Mean endpoint scores




## Augmentation with a benzodiazepine


Review: Pharmacology: Augmentation with a benzodiazepine  
 Comparison: 01 Antidepressant + benzodiazepine v antidepressant + placebo: Efficacy  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Augmentation with a benzodiazepine  
 Comparison: 01 Antidepressant + benzodiazepine v antidepressant + placebo: Efficacy  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Augmentation with a benzodiazepine  
 Comparison: 01 Antidepressant + benzodiazepine v antidepressant + placebo: Efficacy  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Augmentation with a benzodiazepine  
 Comparison: 02 Antidepressant + benzodiazepine v antidepressant + placebo: Tolerability  
 Outcome: 01 Leaving the study early



Review: Pharmacology: Augmentation with a benzodiazepine  
 Comparison: 02 Antidepressant + benzodiazepine v antidepressant + placebo: Tolerability  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Augmentation with a benzodiazepine  
 Comparison: 02 Antidepressant + benzodiazepine v antidepressant + placebo: Tolerability  
 Outcome: 03 Patients reporting side effects




## Augmentation with buspirone

Review: Pharmacology: Refractory depression  
 Comparison: 01 Patients whose depression has not responded to one adequate trial of an antidepressant  
 Outcome: 32 Augmentation with buspirone: Leaving the study early




Review: Pharmacology: Refractory depression  
 Comparison: 01 Patients whose depression has not responded to one adequate trial of an antidepressant  
 Outcome: 33 Augmentation with buspirone: Leaving the study early due to side effects




# Augmentation with pindolol


Review: Pharmacology: Augmentation with pindolol  
 Comparison: 01 Efficacy: (SSRI + Pindolol) v (SSRI + placebo)  
 Outcome: 01 Non-responders at early assessment point (day 10)



Review: Pharmacology: Augmentation with pindolol  
 Comparison: 01 Efficacy: (SSRI + Pindolol) v (SSRI + placebo)  
 Outcome: 02 Non-responders at late assessment point (days 35/42)




Review: Pharmacology: Augmentation with pindolol  
 Comparison: 01 Efficacy: (SSRI + Pindolol) v (SSRI + placebo)  
 Outcome: 03 Non-remitters at early assessment point (days 10/14)







Review: Pharmacology: Augmentation with pindolol  
 Comparison: 01 Efficacy: (SSRI + Pindolol) v (SSRI + placebo)  
 Outcome: 04 Non-remitters at late assessment point (days 21/28/42)




Review: Pharmacology: Augmentation with pindolol  
 Comparison: 01 Efficacy: (SSRI + Pindolol) v (SSRI + placebo)  
 Outcome: 05 Mean scores at early assessment point (day 10)




Review: Pharmacology: Augmentation with pindolol  
 Comparison: 01 Efficacy: (SSRI + Pindolol) v (SSRI + placebo)  
 Outcome: 06 Mean scores at late assessment point (days 21/35/42)




Review: Pharmacology: Augmentation with pindolol  
 Comparison: 02 Tolerability: (SSRI + Pindolol) v (SSRI + placebo)  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Augmentation with pindolol  
 Comparison: 02 Tolerability: (SSRI + Pindolol) v (SSRI + placebo)  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Augmentation with pindolol  
 Comparison: 03 Efficacy: (SSRI + Pindolol) v (SSRI + placebo). Studies providing both early and late assessment outcomes  
 Outcome: 01 Non-responders at early assessment point




Review: Pharmacology: Augmentation with pindolol  
 Comparison: 03 Efficacy: (SSRI + Pindolol) v (SSRI + placebo). Studies providing both early and late assessment outcomes  
 Outcome: 02 Non-responders at late assessment point




Review: Pharmacology: Augmentation with pindolol  
 Comparison: 03 Efficacy: (SSRI + Pindolol) v (SSRI + placebo). Studies providing both early and late assessment outcomes  
 Outcome: 03 Non-remitters at early assessment point




Review: Pharmacology: Augmentation with pindolol  
 Comparison: 03 Efficacy: (SSRI + Pindolol) v (SSRI + placebo). Studies providing both early and late assessment outcomes  
 Outcome: 04 Non-remitters at late assessment point




Review: Pharmacology: Augmentation with pindolol  
 Comparison: 03 Efficacy: (SSRI + Pindolol) v (SSRI + placebo). Studies providing both early and late assessment outcomes  
 Outcome: 05 Mean scores at early assessment point




Review: Pharmacology: Augmentation with pindolol  
 Comparison: 03 Efficacy: (SSRI + Pindolol) v (SSRI + placebo). Studies providing both early and late assessment outcomes  
 Outcome: 06 Mean scores at late assessment point



Review: Pharmacology: Refractory depression  
 Comparison: 02 Patients with treatment resistant depression  
 Outcome: 06 Augmentation with pindolol: Non-remitters at early assessment point (days 10/14)




Review: Pharmacology: Refractory depression  
 Comparison: 02 Patients with treatment resistant depression  
 Outcome: 07 Augmentation with pindolol: Mean score at early assessment point (day 10)






## Augmentation with triiodothyronine (T3)

Review: Pharmacology: Refractory depression  
 Comparison: 01 Patients whose depression has not responded to one adequate trial of an antidepressant  
 Outcome: 25 Augmentation with T3: Number of people not achieving at least 50% reduction in depression



Review: Pharmacology: Refractory depression  
 Comparison: 01 Patients whose depression has not responded to one adequate trial of an antidepressant  
 Outcome: 26 Augmentation with T3: Mean endpoint scores




# Duloxetine

## Dul.01 to 02. Duloxetine versus placebo – acute phase


### Dul.01.01. Acute phase: duloxetine versus placebo by dose – mean change scores

Review: Depression Update: duloxetine  
 Comparison: 01 Acute phase: duloxetine vs placebo  
 Outcome: 01 Mean change scores at endpoint - data for doses above licensed dose (60 mg)




### Dul.01.02. Acute phase: duloxetine versus placebo – mean change scores

Review: Depression Update: duloxetine  
 Comparison: 01 Acute phase: duloxetine vs placebo  
 Outcome: 02 Mean change scores at endpoint - overall




### Dul.01.03. Acute phase: duloxetine versus placebo by dose – non-response

Review: Depression Update: duloxetine  
 Comparison: 01 Acute phase: duloxetine vs placebo  
 Outcome: 03 Non-response - data for doses above licensed dose (60 mg)




### Dul.01.04. Acute phase: duloxetine versus placebo – non-response

Review: Depression Update: duloxetine  
 Comparison: 01 Acute phase: duloxetine vs placebo  
 Outcome: 04 Non-response - overall




### Dul.01.05. Acute phase: duloxetine versus placebo by dose – non-remission

Review: Depression Update: duloxetine  
 Comparison: 01 Acute phase: duloxetine vs placebo  
 Outcome: 05 Non-remission - data for doses above licensed dose (60 mg)




### Dul.01.06. Acute phase: duloxetine versus placebo – non-remission

Review: Depression Update: duloxetine  
 Comparison: 01 Acute phase: duloxetine vs placebo  
 Outcome: 06 Non-remission - overall



**Dul.01.07. Acute phase: duloxetine versus placebo by severity – mean change scores**


Review: Depression Update: duloxetine  
 Comparison: 01 Acute phase: duloxetine vs placebo  
 Outcome: 07 Mean change scores at endpoint (by severity)






**Dul.01.08. Acute phase: duloxetine versus placebo by severity – mean change scores (sensitivity analysis)**

Review: Depression Update: duloxetine  
 Comparison: 01 Acute phase: duloxetine vs placebo  
 Outcome: 08 Sensitivity analysis: Mean change scores at endpoint (by severity)




**Dul.01.09. Acute phase: duloxetine versus placebo – BPI average pain**

Review: Depression Update: duloxetine  
 Comparison: 01 Acute phase: duloxetine vs placebo  
 Outcome: 09 Depression-related pain: BPI item 5 average pain




### Dul.02.01. Acute phase: duloxetine versus placebo by dose – leaving treatment early: any reason

Review: Depression Update: duloxetine  
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability  
 Outcome: 01 Leaving treatment early - any reason (data by doses above licensed dose 60mg)




## Dul.02.02. Acute phase: duloxetine versus placebo – leaving treatment early: any reason

Review: Depression Update: duloxetine  
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability  
 Outcome: 02 Leaving treatment early - any reason (overall)




### Dul.02.03. Acute phase: duloxetine versus placebo by dose – leaving treatment early: adverse reactions

Review: Depression Update: duloxetine  
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability  
 Outcome: 03 Leaving treatment early - adverse reactions (data by doses above licensed dose 60 mg)




### Du1.02.04. Acute phase: duloxetine versus placebo – leaving treatment early: adverse reactions

Review: Depression Update: duloxetine  
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability  
 Outcome: 04 Leaving treatment early - adverse reactions (overall)




### Dul.02.05. Acute phase: duloxetine versus placebo by dose – leaving treatment early: lack of efficacy

Review: Depression Update: duloxetine  
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability  
 Outcome: 05 Leaving treatment early - lack of efficacy (data by doses above licensed dose 60 mg)



### Dul.02.06. Acute phase: duloxetine versus placebo – leaving treatment early: lack of efficacy


Review: Depression Update: duloxetine  
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability  
 Outcome: 06 Leaving treatment early - lack of efficacy (overall)






**Dul.02.07. Acute phase: duloxetine versus placebo – leaving treatment early: lack of efficacy (sensitivity analysis)**

Review: Depression Update: duloxetine  
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability  
 Outcome: 07 Sensitivity analysis: Leaving treatment early - lack of efficacy (overall)




### Dul.02.08. Acute phase: duloxetine versus placebo by dose – number reporting side effects

Review: Depression Update: duloxetine  
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability  
 Outcome: 08 Number reporting side-effects (data by doses above licensed dose 60 mg)




### Du1.02.09. Acute phase: duloxetine versus placebo – number reporting side effects

Review: Depression Update: duloxetine  
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability  
 Outcome: 09 Number reporting side-effects (overall)




### Dul.02.10. Acute phase: duloxetine versus placebo by dose – mean weight change

Review: Depression Update: duloxetine  
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability  
 Outcome: 10 Mean weight change (kg) at endpoint (by doses above licensed dose 60 mg)



### Dul.02.11. Acute phase: duloxetine versus placebo – mean weight change


Review: Depression Update: duloxetine  
 Comparison: 02 Acute phase: duloxetine vs placebo - acceptability and tolerability  
 Outcome: 11 Mean weight change (kg) at endpoint (overall)



### Dul.03 to 04. Duloxetine comparing different doses – acute phase


#### Dul.03.01. Acute phase: duloxetine comparing different doses – mean change scores

Review: Depression Update: duloxetine  
 Comparison: 03 Acute phase: duloxetine at different doses  
 Outcome: 01 Mean change scores at endpoint




### Dul.03.02. Acute phase: duloxetine comparing different doses – non-response

Review: Depression Update: duloxetine  
 Comparison: 03 Acute phase: duloxetine at different doses  
 Outcome: 02 Non-response



### Du1.03.03. Acute phase: duloxetine comparing different doses – non-remission


Review: Depression Update: duloxetine  
 Comparison: 03 Acute phase: duloxetine at different doses  
 Outcome: 03 Non-remission






**Dul.04.01. Acute phase: duloxetine comparing different doses – leaving treatment early: any reason**

Review: Depression Update: duloxetine  
 Comparison: 04 Acute phase: duloxetine at different doses - acceptability and tolerability  
 Outcome: 01 Leaving treatment early - any reason




**Du1.04.02. Acute phase: duloxetine comparing different doses – leaving treatment early: adverse reactions**

Review: Depression Update: duloxetine  
 Comparison: 04 Acute phase: duloxetine at different doses - acceptability and tolerability  
 Outcome: 02 Leaving treatment early - due to adverse reaction




### Dul.04.03. Acute phase: duloxetine comparing different doses – leaving treatment early: lack of efficacy

Review: Depression Update: duloxetine  
 Comparison: 04 Acute phase: duloxetine at different doses - acceptability and tolerability  
 Outcome: 03 Leaving treatment early - lack of efficacy




### Dul.04.04. Acute phase: duloxetine comparing different doses – number reporting side effects

Review: Depression Update: duloxetine  
 Comparison: 04 Acute phase: duloxetine at different doses - acceptability and tolerability  
 Outcome: 04 No reporting side effects



**Du1.04.05. Acute phase: duloxetine comparing different doses – mean weight change**


Review: Depression Update: duloxetine  
 Comparison: 04 Acute phase: duloxetine at different doses - acceptability and tolerability  
 Outcome: 05 Mean weight change (kg) at endpoint



## Dul.05 to 06. Duloxetine versus other antidepressants – acute phase


### Dul.05.01. Acute phase: duloxetine versus other antidepressants – mean change scores

Review: Depression Update: duloxetine  
 Comparison: 05 Acute phase: duloxetine vs other antidepressants  
 Outcome: 01 Mean change scores at endpoint




## Dul.05.02. Acute phase: duloxetine versus other antidepressants – non-response

Review: Depression Update: duloxetine  
 Comparison: 05 Acute phase: duloxetine vs other antidepressants  
 Outcome: 02 Non-response



### Dul.05.03. Acute phase: duloxetine versus other antidepressants – non-remission


Review: Depression Update: duloxetine  
 Comparison: 05 Acute phase: duloxetine vs other antidepressants  
 Outcome: 03 Non-remission






### Dul.06.01. Acute phase: duloxetine versus other antidepressants – leaving treatment early: any reason

Review: Depression Update: duloxetine  
 Comparison: 06 Acute phase: duloxetine vs other antidepressants - acceptability and tolerability  
 Outcome: 01 Leaving treatment early - any reason




## Dul.06.02. Acute phase: duloxetine versus other antidepressants – leaving treatment early: adverse reactions

Review: Depression Update: duloxetine  
 Comparison: 06 Acute phase: duloxetine vs other antidepressants - acceptability and tolerability  
 Outcome: 02 Leaving treatment early - adverse reactions




### Dul.06.03. Acute phase: duloxetine versus other antidepressants – leaving treatment early: lack of efficacy

Review: Depression Update: duloxetine  
 Comparison: 06 Acute phase: duloxetine vs other antidepressants - acceptability and tolerability  
 Outcome: 03 Leaving treatment early - lack of efficacy




### Dul.06.04. Acute phase: duloxetine versus other antidepressants – number reporting side effects

Review: Depression Update: duloxetine  
 Comparison: 06 Acute phase: duloxetine vs other antidepressants - acceptability and tolerability  
 Outcome: 04 Number reporting side effects




### Dul.06.05. Acute phase: duloxetine versus other antidepressants – mean weight change

Review: Depression Update: duloxetine  
 Comparison: 06 Acute phase: duloxetine vs other antidepressants - acceptability and tolerability  
 Outcome: 05 Mean weight change (kg) at endpoint



### Du1.06.06. Acute phase: duloxetine versus other antidepressants – mean weight change (sensitivity analysis)


Review: Depression Update: duloxetine  
 Comparison: 06 Acute phase: duloxetine vs other antidepressants - acceptability and tolerability  
 Outcome: 06 Sensitivity analysis: Mean weight change (kg) at endpoint



## Dul.07. Duloxetine versus placebo – continuation phase for partial responders


### Dul.07.01. Continuation phase (for partial responders): duloxetine versus placebo – mean change scores

Review: Depression Update: duloxetine  
 Comparison: 07 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs placebo  
 Outcome: 01 Mean change scores from end of acute phase




### Dul.07.02. Continuation phase (for partial responders): duloxetine versus placebo – leaving treatment early: any reason

Review: Depression Update: duloxetine  
 Comparison: 07 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs placebo  
 Outcome: 02 Leaving treatment early - for any reason




### Dul.07.03. Continuation phase (for partial responders): duloxetine versus placebo – leaving treatment early: adverse reactions

Review: Depression Update: duloxetine  
 Comparison: 07 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs placebo  
 Outcome: 03 Leaving treatment early - adverse reactions



### Dul.07.04. Continuation phase (for partial responders): duloxetine versus placebo – leaving treatment early: lack of efficacy

Review: Depression Update: duloxetine  
 Comparison: 07 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs placebo  
 Outcome: 04 Leaving treatment early - lack of efficacy






## Dul.08. Duloxetine comparing different doses – continuation phase for partial responders


### Dul.08.01. Continuation phase (for partial responders): duloxetine comparing different doses – mean change scores

Review: Depression Update: duloxetine  
 Comparison: 08 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine at different doses  
 Outcome: 01 Mean change scores from end of acute phase




### Dul.08.02. Continuation phase (for partial responders): duloxetine comparing different doses – leaving treatment early: any reason

Review: Depression Update: duloxetine  
 Comparison: 08 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine at different doses  
 Outcome: 02 Leaving treatment early - for any reason




**DuI.08.03. Continuation phase (for partial responders): duloxetine comparing different doses – leaving treatment early: adverse reactions**

Review: Depression Update: duloxetine  
 Comparison: 08 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine at different doses  
 Outcome: 03 Leaving treatment early - adverse reactions



**DuI.08.04. Continuation phase (for partial responders): duloxetine comparing different doses – leaving treatment early: lack of efficacy**


Review: Depression Update: duloxetine  
 Comparison: 08 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine at different doses  
 Outcome: 04 Leaving treatment early - lack of efficacy



### Dul.09. Duloxetine versus other antidepressants – continuation phase for partial responders


#### Dul.09.01. Continuation phase (for partial responders): duloxetine versus other antidepressants – mean change scores

Review: Depression Update: duloxetine  
 Comparison: 09 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs other drugs  
 Outcome: 01 Mean change scores from end of acute phase




#### Dul.09.02. Continuation phase (for partial responders): duloxetine versus other antidepressants – leaving treatment early: any reason

Review: Depression Update: duloxetine  
 Comparison: 09 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs other drugs  
 Outcome: 02 Leaving treatment early - for any reason




**DuI.09.03. Continuation phase (for partial responders): duloxetine versus other antidepressants – leaving treatment early: adverse reactions**

Review: Depression Update: duloxetine  
 Comparison: 09 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs other drugs  
 Outcome: 03 Leaving treatment early - adverse reactions



**DuI.09.04. Continuation phase (for partial responders): duloxetine versus other antidepressants – leaving treatment early: lack of efficacy**

Review: Depression Update: duloxetine  
 Comparison: 09 Continuation phase for those with 30% improvement in baseline HAMD-17 scores: duloxetine vs other drug  
 Outcome: 04 Leaving treatment early - lack of efficacy




**Dul.10. Duloxetine versus placebo – continuation phase for those achieving remission**

No efficacy data

**Dul.11. Duloxetine versus other antidepressants – continuation phase for all**


**Dul.11.01. Continuation phase (for all): duloxetine versus other antidepressants – mean change scores**

Review: Depression Update: duloxetine  
 Comparison: 11 Continuation phase no entry criteria: duloxetine vs other drugs  
 Outcome: 01 Mean scores at endpoint




**Dul.11.02. Continuation phase (for all): duloxetine versus other antidepressants – non-response**

Review: Depression Update: duloxetine  
 Comparison: 11 Continuation phase no entry criteria: duloxetine vs other drugs  
 Outcome: 02 Non-response




### Dul.11.03. Continuation phase (for all): duloxetine versus other antidepressants – non-remission

Review: Depression Update: duloxetine  
 Comparison: 11 Continuation phase no entry criteria: duloxetine vs other drugs  
 Outcome: 03 Non-remission




### Dul.11.04. Continuation phase (for all): duloxetine versus other antidepressants – leaving treatment early: any reason

Review: Depression Update: duloxetine  
 Comparison: 11 Continuation phase no entry criteria: duloxetine vs other drugs  
 Outcome: 04 Leaving treatment early - any reason




**Dul.11.05. Continuation phase (for all): duloxetine versus other antidepressants – adverse reactions**

Review: Depression Update: duloxetine  
 Comparison: 11 Continuation phase no entry criteria: duloxetine vs other drugs  
 Outcome: 05 Leaving treatment early - adverse reactions



**Dul.11.06. Continuation phase (for all): duloxetine versus other antidepressants – lack of efficacy**

Review: Depression Update: duloxetine  
 Comparison: 11 Continuation phase no entry criteria: duloxetine vs other drugs  
 Outcome: 06 Leaving treatment early - lack of efficacy




# Escitalopram

## Esc.01. Escitalopram versus placebo

### Esc.01.01. Non-response data


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 01 Escitalopram vs placebo  
 Outcome: 01 Non-response






### Esc.01.02. Non-remission data

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 01 Escitalopram vs placebo  
 Outcome: 02 Non-remission




### Esc.01.03. Mean endpoint depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 01 Escitalopram vs placebo  
 Outcome: 03 Mean endpoint depression scores (clinician-rated)




### Esc.01.04. Mean change depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 01 Escitalopram vs placebo  
 Outcome: 04 Mean change depression scores (clinician-rated)




### Esc.01.05. Number leaving treatment early for any reason

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 01 Escitalopram vs placebo  
 Outcome: 05 Leaving treatment early for any reason




### Esc.01.06. Number leaving treatment early due to side effects

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 01 Escitalopram vs placebo  
 Outcome: 06 Leaving treatment early due to side effects



### Esc.01.07. Number reporting side effects


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 01 Escitalopram vs placebo  
 Outcome: 07 Patients reporting side effects



## Esc.02. Escitalopram versus all other antidepressants


### Esc.02.01. Non-response data

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 02 Escitalopram vs all other ADs  
 Outcome: 01 Non-response



## Esc.02.02. Non-remission data


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 02 Escitalopram vs all other ADs  
 Outcome: 02 Non-remission






**Esc.02.03. Mean endpoint depression scores (clinician-rated)**

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 02 Escitalopram vs all other ADs  
 Outcome: 03 Mean endpoint depression scores (clinician-rated)




### Esc.02.04. mean change depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 02 Escitalopram vs all other ADs  
 Outcome: 04 Mean change depression scores (clinician-rated)




### Esc.02.05. Number leaving treatment early for any reason

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 02 Escitalopram vs all other ADs  
 Outcome: 05 Leaving treatment early for any reason




**Esc.02.06. Number leaving treatment early due to side effects**

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 02 Escitalopram vs all other ADs  
 Outcome: 06 Leaving treatment early due to side effects



### Esc.02.07. Number reporting side effects


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 02 Escitalopram vs all other ADs  
 Outcome: 07 Number reporting side effects



### Esc.03. Escitalopram versus SSRIs


#### Esc.03.01. Non-response data

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 03 Escitalopram vs SSRIs  
 Outcome: 01 Non-response (vs SSRIs)




### Esc.03.02. Non-response data (sensitivity analysis)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 03 Escitalopram vs SSRIs  
 Outcome: 02 Non-response (sensitivity analysis)



### Esc.03.03. Non-remission data


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 03 Escitalopram vs SSRIs  
 Outcome: 03 Number not achieving remission at endpoint (vs SSRIs)






### Esc.03.04. Non-remission data (sensitivity analysis)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 03 Escitalopram vs SSRIs  
 Outcome: 04 Number not achieving remission at endpoint (vs SSRIs) (sensitivity analysis)




### Esc.03.05. Mean endpoint depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 03 Escitalopram vs SSRIs  
 Outcome: 05 Mean endpoint scores (clinician rated) (vs SSRIs)




### Esc.03.06. Mean change depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 03 Escitalopram vs SSRIs  
 Outcome: 06 Mean change (clinician rated) (vs SSRIs)




### Esc.03.07. Number leaving the study early for any reason

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 03 Escitalopram vs SSRIs  
 Outcome: 07 Leaving the study early for any reason (vs SSRIs)




### Esc.03.08. Number leaving the study early due to side effects

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 03 Escitalopram vs SSRIs  
 Outcome: 08 Leaving the study early due to side effects (vs SSRIs)




### Esc.03.09. Number reporting side effects

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 03 Escitalopram vs SSRIs  
 Outcome: 09 Patients reporting side effects (vs SSRIs)



### Esc.03.10. Number reporting side effects (sensitivity analysis)


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 03 Escitalopram vs SSRIs  
 Outcome: 10 Patients reporting side effects (vs SSRIs) (sensitivity analysis)



## Esc.04. Escitalopram versus non-SSRIs

### Esc.04.01. Non-response data


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)  
 Outcome: 01 Non-response






### Esc.04.02. Non-remission data

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)  
 Outcome: 02 Number not achieving remission at endpoint




**Esc.04.03. Mean endpoint depression scores (clinician-rated)**

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)  
 Outcome: 03 Mean endpoint scores (clinician rated)




### Esc.04.04. Mean change depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)  
 Outcome: 04 Mean change (clinician rated)




### Esc.04.05. Number leaving the study early for any reason

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)  
 Outcome: 05 Leaving the study early for any reason




### Esc.04.06. Number leaving the study early due to side effects

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)  
 Outcome: 06 Leaving the study early due to side effects



**Esc.04.07. Number reporting side effects**


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 04 Escitalopram vs other ADs (non SSRIs)  
 Outcome: 07 Patients reporting side effects



## Esc.05. Escitalopram versus all other antidepressants – citalopram separated


### Esc.05.01. Non-response data

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)  
 Outcome: 01 Non-response



## Esc.05.02. Non-remission data


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)  
 Outcome: 02 Non-remission






### Esc.05.03. Mean endpoint depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)  
 Outcome: 03 Mean endpoint depression scores (clinician-rated)




### Esc.05.04. Mean change depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)  
 Outcome: 04 Mean change scores (clinician-rated)




### Esc.05.05. Number leaving treatment early for any reason

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)  
 Outcome: 05 Leaving treatment early for any reason




### Esc.05.06. Number leaving treatment early due to side effects

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)  
 Outcome: 06 Leaving treatment early due to side effects



### Esc.05.07. Number reporting side effects


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 05 Escitalopram vs all other ADs (citalopram separated)  
 Outcome: 07 Number reporting side effects



## Esc.06. Escitalopram: overall efficacy – ordered by baseline severity


### Esc.06.01. Non-response data

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 06 Overall efficacy (ordered by baseline severity)  
 Outcome: 01 Number not achieving => 50% reduction in outcome score at endpoint




## Esc.06.02. Non-remission data

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 06 Overall efficacy (ordered by baseline severity)  
 Outcome: 02 Number not achieving remission at endpoint



### Esc.06.03. Mean endpoint depression scores (clinician-rated)


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 06 Overall efficacy (ordered by baseline severity)  
 Outcome: 03 Mean endpoint scores (clinician rated)





### Esc.06.04. Mean change depression scores (clinician-rated)


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 06 Overall efficacy (ordered by baseline severity)  
 Outcome: 04 Mean change (clinician rated)



## Esc.07. Escitalopram: overall acceptability and tolerability – ordered by baseline severity


### Esc.07.01. Number leaving the study early for any reason

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 07 Overall acceptability and tolerability (ordered by baseline severity)  
 Outcome: 01 Leaving the study early for any reason




### Esc.07.02. Number leaving the study early due to side effects

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 07 Overall acceptability and tolerability (ordered by baseline severity)  
 Outcome: 02 Leaving the study early due to side effects



### Esc.07.03. Number reporting side effects


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 07 Overall acceptability and tolerability (ordered by baseline severity)  
 Outcome: 03 Patients reporting side effects



## Esc.08. Escitalopram: overall efficacy versus active treatment – by comparator drug


### Esc.08.01. Non-response data (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)  
 Outcome: 01 Number not achieving => 50% reduction in outcome score (vs SSRIs)




### Esc.08.02. Non-response data (versus SSRIs) (sensitivity analysis)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)  
 Outcome: 02 Number not achieving => 50% reduction in outcome score (vs SSRIs) (sensitivity analysis)




### Esc.08.03. Non-response data (versus other anti-depressants)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)  
 Outcome: 03 Non-response (vs other antidepressants)



### Esc.08.04. Non-remission data (versus SSRIs)


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)  
 Outcome: 04 Number not achieving remission at endpoint (vs SSRIs)






### Esc.08.05. Non-remission data (versus SSRIs) (sensitivity analysis)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)  
 Outcome: 05 Number not achieving remission at endpoint (vs SSRIs) (sensitivity analysis)




**Esc.08.06. Non-remission data (versus other antidepressants)**

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)  
 Outcome: 06 Number not achieving remission at endpoint (vs other ADs)




### Esc.08.07. Mean endpoint depression scores (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)  
 Outcome: 07 Mean endpoint scores (clinician rated) (vs SSRIs)




**Esc.08.08. Mean endpoint depression scores (clinician-rated) (versus all other antidepressants)**

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)  
 Outcome: 08 Mean endpoint scores (clinician rated) (vs other ADs)




### Esc.08.09. Mean depression change scores (clinician-rated) (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)  
 Outcome: 09 Mean change (clinician rated) (vs SSRIs)



### Esc.08.10. Mean depression change scores (clinician-rated) (versus all other antidepressants)


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 08 Overall efficacy v Active Treatment (by comparator drug)  
 Outcome: 10 Mean change (clinician rated) (vs ADs)



## Esc.09. Escitalopram: overall acceptability and tolerability versus active treatment - by comparator drug


### Esc.09.01. Number leaving the study early for any reason (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 09 Overall acceptability and tolerability v Active Treatment (by comparator drug)  
 Outcome: 01 Leaving the study early for any reason (vs SSRIs)



### Esc.09.02. Number leaving the study early for any reason (versus all other antidepressants)


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 09 Overall acceptability and tolerability v Active Treatment (by comparator drug)  
 Outcome: 02 Leaving the study early for any reason (vs other ADs)






### Esc.09.03. Number leaving the study early due to side effects (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 09 Overall acceptability and tolerability v Active Treatment (by comparator drug)  
 Outcome: 03 Leaving the study early due to side effects (vs SSRIs)




**Esc.09.04. Number leaving the study early due to side effects (versus all other antidepressants)**

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 09 Overall acceptability and tolerability v Active Treatment (by comparator drug)  
 Outcome: 04 Leaving the study early due to side effects (vs other ADs)




### Esc.09.05. Number reporting side effects (versus SSRIs)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 09 Overall acceptability and tolerability v Active Treatment (by comparator drug)  
 Outcome: 05 Patients reporting side effects (vs SSRIs)



**Esc.09.06. Number reporting side effects (versus all other antidepressants)**


Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 09 Overall acceptability and tolerability v Active Treatment (by comparator drug)  
 Outcome: 06 Patients reporting side effects (vs other ADs)



## Esc.10. Escitalopram: overall efficacy - by dose


### Esc.10.01. Non-response data

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 10 Overall efficacy (by dose)  
 Outcome: 01 Number not achieving =>50% reduction in outcome score at endpoint




### Esc.10.02. Non-remission data

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 10 Overall efficacy (by dose)  
 Outcome: 02 Number not achieving remission at endpoint




### Esc.10.03. Mean endpoint depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 10 Overall efficacy (by dose)  
 Outcome: 03 Mean endpoint scores (clinician rated)



### Esc.10.04. Mean change depression scores (clinician-rated)

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 10 Overall efficacy (by dose)  
 Outcome: 04 Mean change (clinician rated)






# Esc.11. Escitalopram: overall acceptability and tolerability – by dose


## Esc.11.01. Number leaving the study early for any reason

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 11 Overall acceptability and tolerability (by dose)  
 Outcome: 01 Leaving the study early for any reason




### Esc.11.02. Number leaving the study early due to side effects

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 11 Overall acceptability and tolerability (by dose)  
 Outcome: 02 Leaving the study early due to side effects




### Esc.11.03. Number reporting side effects

Review: Depression Update Pharmacology: Escitalopram  
 Comparison: 11 Overall acceptability and tolerability (by dose)  
 Outcome: 03 Patients reporting side effects




# Low dose TCAs


Review: Pharmacology: Low dose tricyclics  
 Comparison: 01 Efficacy of low dose TCAs vs high dose TCAs  
 Outcome: 01 Number of people not achieving remission




Review: Pharmacology: Low dose tricyclics  
 Comparison: 01 Efficacy of low dose TCAs vs high dose TCAs  
 Outcome: 02 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Low dose tricyclics  
 Comparison: 01 Efficacy of low dose TCAs vs high dose TCAs  
 Outcome: 03 Mean endpoint score




Review: Pharmacology: Low dose tricyclics  
 Comparison: 02 Tolerability of low dose TCAs vs high dose TCAs  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Low dose tricyclics  
 Comparison: 02 Tolerability of low dose TCAs v high dose TCAs  
 Outcome: 02 Leaving the study early due to side effects



Review: Pharmacology: Low dose tricyclics  
 Comparison: 03 Efficacy of low dose TCAs vs placebo  
 Outcome: 01 Mean endpoint score




Review: Pharmacology: Low dose tricyclics  
 Comparison: 03 Efficacy of low dose TCAs v placebo  
 Outcome: 02 Number of people not achieving at least 50% reduction in depression score




# Mirtazapine

Review: Pharmacology: Mirtazapine  
 Comparison: 01 Overall efficacy  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score







Review: Pharmacology: Mirtazapine  
 Comparison: 01 Overall efficacy  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Mirtazapine  
 Comparison: 01 Overall efficacy  
 Outcome: 03 Mean end point scores




Review: Pharmacology: Mirtazapine  
 Comparison: 01 Overall efficacy  
 Outcome: 04 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine  
 Comparison: 01 Overall efficacy  
 Outcome: 05 Number of inpatients not achieving remission




Review: Pharmacology: Mirtazapine  
 Comparison: 01 Overall efficacy  
 Outcome: 06 Mean end point scores in Inpatient studies




Review: Pharmacology: Mirtazapine  
 Comparison: 01 Overall efficacy  
 Outcome: 07 Number of outpatients not achieving at least 50% reduction in depression score



Review: Pharmacology: Mirtazapine  
 Comparison: 01 Overall efficacy  
 Outcome: 08 Number of outpatients not achieving remission




Review: Pharmacology: Mirtazapine  
 Comparison: 01 Overall efficacy  
 Outcome: 09 Mean end point scores in Outpatient studies







Review: Pharmacology: Mirtazapine  
 Comparison: 02 Overall tolerability  
 Outcome: 01 Leaving the study early




Review: Pharmacology; Mirtazapine  
 Comparison: 02 Overall tolerability  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Mirtazapine  
 Comparison: 02 Overall tolerability  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Mirtazapine  
 Comparison: 02 Overall tolerability  
 Outcome: 04 Inpatients leaving the study early




Review: Pharmacology: Mirtazapine  
 Comparison: 02 Overall tolerability  
 Outcome: 05 Inpatients leaving the study early due to side effects




Review: Pharmacology: Mirtazapine  
 Comparison: 02 Overall tolerability  
 Outcome: 06 Inpatients reporting side effects



Review: Pharmacology Mirtazapine  
 Comparison: 02 Overall tolerability  
 Outcome: 07 Outpatients leaving the study early




Review: Pharmacology Mirtazapine  
 Comparison: 02 Overall tolerability  
 Outcome: 08 Outpatients leaving the study early due to side effects







Review: Pharmacology: Mirtazapine  
 Comparison: 02 Overall tolerability  
 Outcome: 09 Outpatients reporting side effects




Review: Pharmacology: Mirtazapine  
 Comparison: 02 Overall tolerability  
 Outcome: 10 Leaving the study early in primary care




Review: Pharmacology: Mirtazapine  
 Comparison: 02 Overall tolerability  
 Outcome: 11 Leaving the study early due to side effects in primary care




Review: Pharmacology: Mirtazapine  
 Comparison: 02 Overall tolerability  
 Outcome: 12 Primary care patients reporting side effects




Review: Pharmacology: Mirtazapine  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 02 Mean end point scores




Review: Pharmacology: Mirtazapine  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 04 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 05 Mean end point scores in Inpatient studies




Review: Pharmacology: Mirtazapine  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 07 Number of outpatients not achieving at least 50% reduction in depression score



Review: Pharmacology: Mirtazapine  
 Comparison: 03 Efficacy against TCAs  
 Outcome: 08 Mean end point scores in Outpatient studies




Review: Pharmacology: Mirtazapine  
 Comparison: 04 Tolerability against TCAs  
 Outcome: 01 Leaving the study early







Review: Pharmacology: Mirtazapine  
 Comparison: 04 Tolerability against TCAs  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Mirtazapine  
 Comparison: 05 Efficacy against TCAs and related ADs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine  
 Comparison: 05 Efficacy against TCAs and related ADs  
 Outcome: 02 Mean end point scores




Review: Pharmacology: Mirtazapine  
 Comparison: 05 Efficacy against TCAs and related ADs  
 Outcome: 03 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine  
 Comparison: 05 Efficacy against TCAs and related ADs  
 Outcome: 05 Mean end point scores in Inpatient studies




Review: Pharmacology: Mirtazapine  
 Comparison: 05 Efficacy against TCAs and related ADs  
 Outcome: 07 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine  
 Comparison: 05 Efficacy against TCAs and related ADs  
 Outcome: 08 Mean end point scores in Outpatient studies



Review: Pharmacology: Mirtazapine  
 Comparison: 06 Tolerability against TCAs and related ADs  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Mirtazapine  
 Comparison: 06 Tolerability against TCAs and related ADs  
 Outcome: 02 Leaving the study early due to side effects







Review: Pharmacology: Mirtazapine  
 Comparison: 06 Tolerability against TCAs and related ADs  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Mirtazapine  
 Comparison: 07 Efficacy against SSRIs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine  
 Comparison: 07 Efficacy against SSRIs  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Mirtazapine  
 Comparison: 07 Efficacy against SSRIs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Mirtazapine  
 Comparison: 07 Efficacy against SSRIs  
 Outcome: 04 Number of outpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Mirtazapine  
 Comparison: 07 Efficacy against SSRIs  
 Outcome: 05 Number of outpatients not achieving remission



Review: Pharmacology: Mirtazapine  
 Comparison: 07 Efficacy against SSRIs  
 Outcome: 06 Mean endpoint scores in outpatient studies




Review: Pharmacology: Mirtazapine  
 Comparison: 08 Tolerability against SSRIs  
 Outcome: 01 Leaving the study early







Review: Pharmacology: Mirtazapine  
 Comparison: 08 Tolerability against SSRIs  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Mirtazapine  
 Comparison: 08 Tolerability against SSRIs  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Mirtazapine  
 Comparison: 09 Efficacy at 1 or 2 weeks  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score



Review: Pharmacology: Mirtazapine  
 Comparison: 09 Efficacy at 1 or 2 weeks  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Mirtazapine  
 Comparison: 09 Efficacy at 1 or 2 weeks  
 Outcome: 03 Mean endpoint scores




## **Moclobemide**

Review: Pharmacology: Moclobemide  
 Comparison: 01 Efficacy: Moclobemide vs antidepressants  
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Moclobemide  
 Comparison: 01 Efficacy: Moclobemide vs antidepressants  
 Outcome: 02 Sensitivity analysis: Mean endpoint scores







Review: Pharmacology: Moclobemide  
 Comparison: 01 Efficacy: Moclobemide vs antidepressants  
 Outcome: 03 Non-responders




Review: Pharmacology: Moclobemide  
 Comparison: 01 Efficacy: Moclobemide vs antidepressants  
 Outcome: 04 Non-remitters




Review: Pharmacology: Moclobemide  
 Comparison: 02 Tolerability: Moclobemide vs antidepressants  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Moclobemide  
 Comparison: 02 Tolerability: Moclobemide vs antidepressants  
 Outcome: 02 Leaving the study due to side effects




Review: Pharmacology: Moclobemide  
 Comparison: 02 Tolerability: Moclobemide vs antidepressants  
 Outcome: 03 Patients reporting adverse events




Review: Pharmacology: Moclobemide  
 Comparison: 03 Efficacy: Moclobemide vs SSRIs  
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Moclobemide  
 Comparison: 03 Efficacy: Moclobemide vs SSRIs  
 Outcome: 02 Sensitivity analysis: Mean endpoint scores



Review: Pharmacology: Moclobemide  
 Comparison: 03 Efficacy: Moclobemide vs SSRIs  
 Outcome: 03 Non-responders




Review: Pharmacology: Moclobemide  
 Comparison: 03 Efficacy: Moclobemide v SSRIs  
 Outcome: 04 Non-remitters







Review: Pharmacology: Moclobemide  
 Comparison: 04 Tolerability: Moclobemide vs SSRIs  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Moclobemide  
 Comparison: 04 Tolerability: Moclobemide vs SSRIs  
 Outcome: 02 Leaving the study due to side effects




Review: Pharmacology: Moclobemide  
 Comparison: 04 Tolerability: Moclobemide vs SSRIs  
 Outcome: 03 Patients reporting adverse events




Review: Pharmacology: Moclobemide  
 Comparison: 05 Efficacy: Moclobemide vs TCAs  
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Moclobemide  
 Comparison: 05 Efficacy: Moclobemide vs TCAs  
 Outcome: 02 Sensitivity analysis: Mean endpoint scores




Review: Pharmacology: Moclobemide  
 Comparison: 05 Efficacy: Moclobemide vs TCAs  
 Outcome: 03 Non-responders



Review: Pharmacology: Moclobemide  
 Comparison: 05 Efficacy: Moclobemide vs TCAs  
 Outcome: 04 Non-remitters




Review: Pharmacology: Moclobemide  
 Comparison: 06 Tolerability: Moclobemide vs TCAs  
 Outcome: 01 Leaving the study early







Review: Pharmacology: Moclobemide  
 Comparison: 06 Tolerability: Moclobemide vs TCAs  
 Outcome: 02 Leaving the study due to side effects




Review: Pharmacology: Moclobemide  
 Comparison: 06 Tolerability: Moclobemide vs TCAs  
 Outcome: 03 Patients reporting adverse events




Review: Pharmacology: Moclobemide  
 Comparison: 07 Inpatients: Moclobemide vs antidepressants  
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Moclobemide  
 Comparison: 07 Inpatients: Moclobemide vs antidepressants  
 Outcome: 02 Sensitivity analysis: Mean endpoint scores




Review: Pharmacology: Moclobemide  
 Comparison: 07 Inpatients: Moclobemide vs antidepressants  
 Outcome: 03 Non-responders




Review: Pharmacology: Moclobemide  
 Comparison: 07 Inpatients: Moclobemide vs antidepressants  
 Outcome: 04 Leaving the study early



Review: Pharmacology: Moclobemide  
 Comparison: 07 Inpatients: Moclobemide vs antidepressants  
 Outcome: 05 Leaving the study due to side effects




Review: Pharmacology: Moclobemide  
 Comparison: 07 Inpatients: Moclobemide vs antidepressants  
 Outcome: 06 Patients reporting adverse events







Review: Pharmacology: Moclobemide  
 Comparison: 08 Outpatients: Moclobemide vs antidepressants  
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Moclobemide  
 Comparison: 08 Outpatients: Moclobemide vs antidepressants  
 Outcome: 02 Sensitivity analysis: Mean endpoint scores




Review: Pharmacology: Moclobemide  
 Comparison: 08 Outpatients: Moclobemide vs antidepressants  
 Outcome: 03 Non-responders



Review: Pharmacology: Moclobemide  
 Comparison: 08 Outpatients: Moclobemide vs antidepressants  
 Outcome: 04 Non-remitters




Review: Pharmacology: Moclobemide  
 Comparison: 08 Outpatients: Moclobemide vs antidepressants  
 Outcome: 05 Leaving the study early







Review: Pharmacology: Moclobemide  
 Comparison: 08 Outpatients: Moclobemide vs antidepressants  
 Outcome: 07 Patients reporting adverse events



Review: Pharmacology: Moclobemide  
 Comparison: 09 Primary care patients: Moclobemide vs antidepressants  
 Outcome: 01 Non-responders




Review: Pharmacology: Moclobemide  
 Comparison: 09 Primary care patients: Moclobemide vs antidepressants  
 Outcome: 02 Non-remitters







Review: Pharmacology: Moclobemide  
 Comparison: 09 Primary care patients: Moclobemide vs antidepressants  
 Outcome: 03 Leaving the study early




Review: Pharmacology: Moclobemide  
 Comparison: 09 Primary care patients: Moclobemide vs antidepressants  
 Outcome: 04 Leaving the study due to side effects




Review: Pharmacology: Moclobemide  
 Comparison: 09 Primary care patients: Moclobemide vs antidepressants  
 Outcome: 05 Patients reporting adverse events




Review: Pharmacology: Moclobemide  
 Comparison: 10 Efficacy: Moclobemide vs placebo  
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Moclobemide  
 Comparison: 10 Efficacy: Moclobemide vs placebo  
 Outcome: 02 Non-responders




Review: Pharmacology: Moclobemide  
 Comparison: 10 Efficacy: Moclobemide vs placebo  
 Outcome: 03 Non-remitters




Review: Pharmacology: Moclobemide  
 Comparison: 11 Tolerability: Moclobemide vs placebo  
 Outcome: 01 Leaving the study early



Review: Pharmacology: Moclobemide  
 Comparison: 11 Tolerability: Moclobemide vs placebo  
 Outcome: 02 Leaving the study due to side effects



Review: Pharmacology: Moclobemide  
 Comparison: 11 Tolerability: Moclobemide vs placebo  
 Outcome: 03 Patients reporting adverse events




## Next-step treatments

### Next-step 01. Dose escalation


#### Next-step 01.01. Dose escalation – mean depression scores

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 01 Dose escalation  
 Outcome: 01 Mean depression scores




### Next-step 01.02. Dose escalation – number not achieving remission

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 01 Dose escalation  
 Outcome: 02 Number not achieving remission



### Next-step 01.03. Dose escalation – number not achieving response

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 01 Dose escalation  
 Outcome: 03 Number not achieving response






**Next-step 01.04. Dose escalation – leaving treatment early for any reason**

Review: Depression update: pharmacology – next-step treatments


Comparison: 01 Dose escalation

Outcome: 04 Leaving treatment early for any reason




### Next-step 01.05. Dose escalation – leaving treatment early due to side effects

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 01 Dose escalation  
 Outcome: 05 Leaving treatment early due to side effects




**Next-step 01.06. Dose escalation – leaving treatment early due to lack of efficacy**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 01 Dose escalation  
 Outcome: 06 Leaving treatment early due to lack of efficacy



**Next-step 01.07. Dose escalation – number reporting side effects**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 01 Dose escalation  
 Outcome: 07 Number reporting side effects




# Next-step switching

## Next-step 02. Switching: continuing antidepressants versus switching


### Next-step 02.01. Switching: continuing antidepressants versus switching – number not achieving response

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 02 Switching: continuing AD vs switching  
 Outcome: 01 Number not achieving response




## Next-step 02.02. Switching: continuing antidepressants versus switching – number not achieving remission

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 02 Switching: continuing AD vs switching  
 Outcome: 02 Number not achieving remission




**Next-step 02.03. Switching: continuing antidepressants versus switching – mean endpoint scores (self-rated)**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 02 Switching: continuing AD vs switching  
 Outcome: 03 Other comparisons: mean endpoint scores (self-rated)



## Next-step 02.04. Switching: continuing antidepressants versus switching – leaving treatment early for any reason


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 02 Switching: continuing AD vs switching  
 Outcome: 04 Other comparisons: number leaving treatment early for any reason






## Next-step 02.05. Switching: continuing antidepressants versus switching – leaving treatment early because of side effects

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 02 Switching: continuing AD vs switching  
 Outcome: 05 Other comparisons: number leaving treatment early because of side effects



**Next-step 02.06. Switching: continuing antidepressants versus switching – number reporting side effects**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 02 Switching: continuing AD vs switching  
 Outcome: 06 Other comparisons: number reporting side effects



### Next-step 03. Switching: switching to single or combination drugs


#### Next-step 03.01. Switching: switching to venlafaxine versus switch to another drug – efficacy data

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 03 Switching: switching to single or combination drugs  
 Outcome: 01 Switch to venlafaxine vs switch to another antidepressant (efficacy)




### Next-step 03.02. Switching: switching to venlafaxine versus switch to another drug – efficacy data

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 03 Switching: switching to single or combination drugs  
 Outcome: 02 Switch to venlafaxine vs switch to another antidepressant (efficacy)




### Next-step 03.03. Switching: switching to venlafaxine versus switch to another drug – acceptability/tolerability data

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 03 Switching: switching to single or combination drugs  
 Outcome: 03 Switch to venlafaxine vs switch to another antidepressant (acceptability/tolerability)



### Next-step 03.04. Switching: switching to fluoxetine versus olanzapine – efficacy data

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 03 Switching: switching to single or combination drugs  
 Outcome: 04 Switch to fluoxetine vs switch to olanzapine (efficacy)




### Next-step 03.05. Switching: switching to fluoxetine versus olanzapine – efficacy data

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 03 Switching: switching to single or combination drugs  
 Outcome: 05 Switch to fluoxetine vs switch to olanzapine (efficacy)




**Next-step 03.06. Switching: switching to fluoxetine versus olanzapine – acceptability/tolerability data**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 03 Switching: switching to single or combination drugs  
 Outcome: 06 Switch to fluoxetine vs switch to olanzapine (acceptability/tolerability)




### Next-step 03.07. Switching: switching to augmentation strategy versus switch to single drug – efficacy data

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 03 Switching: switching to single or combination drugs  
 Outcome: 07 Switch to augmentation strategy vs switch to single drug: efficacy outcomes



### Next-step 03.08. Switching: switching to augmentation strategy versus switch to single drug – efficacy data


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 03 Switching: switching to single or combination drugs  
 Outcome: 08 Switch to augmentation strategy vs switch to single drug: efficacy outcomes





### Next-step 03.09. Switching: switching to augmentation strategy versus switch to single drug – acceptability/tolerability data


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 03 Switching: switching to single or combination drugs  
 Outcome: 09 Switch to augmentation strategy vs switch to single drug: acceptability/tolerability



### Next-step 04. Switching to a single drug


#### Next-step 04.01. Switching: switching to single drug (randomised first step) – non-response

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 04 Switching: switching to single drug (randomised first-step drug)  
 Outcome: 01 Switching strategies: Number of people not achieving at least 50% reduction in depression score




#### Next-step 04.02. Switching: switching to single drug (randomised first step) – mean endpoint data

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 04 Switching: switching to single drug (randomised first-step drug)  
 Outcome: 02 Switching strategies: Mean endpoint scores



**Next-step 04.03. Switching: switching to single drug (randomised first step) – leaving treatment early**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 04 Switching: switching to single drug (randomised first-step drug)  
 Outcome: 03 Switching strategies: Leaving the study early



**Next-step 05. Switching: single antidepressants versus augmentation strategy**


**Next-step 05.01. Switching: single antidepressants versus augmentation strategy – non-remission**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 05 Switching: single AD vs augmentation strategy (open-label data)  
 Outcome: 01 Number not achieving remission




### Next-step 05.02. Switching: single antidepressants versus augmentation strategy – mean endpoint data

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 05 Switching: single AD vs augmentation strategy (open-label data)  
 Outcome: 02 Mean endpoint scores (self-rated)




### Next-step 05.03. Switching: single antidepressants versus augmentation strategy – leaving treatment early for any reason

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 05 Switching: single AD vs augmentation strategy (open-label data)  
 Outcome: 03 Number leaving treatment early for any reason



**Next-step 05.04. Switching: single antidepressants versus augmentation strategy – leaving treatment early due to side effects**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 05 Switching: single AD vs augmentation strategy (open-label data)  
 Outcome: 04 Number leaving treatment early because of side effects



**Next-step 06. Switching: single antidepressants (open-label data)**


**Next-step 06.01. Switching: single antidepressants (open-label data) – non-remission**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 06 Switching: switching to single drug (open-label data)  
 Outcome: 01 Number not achieving remission




### Next-step 06.02. Switching: single antidepressants (open-label data) – mean endpoint data

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 06 Switching: switching to single drug (open-label data)  
 Outcome: 02 Mean endpoint data




**Next-step 06.03. Switching: single antidepressants (open-label data) – leaving treatment early for any reason**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 06 Switching: switching to single drug (open-label data)  
 Outcome: 03 Leaving the study early for any reason



**Next-step 06.04. Switching: single antidepressants (open-label data) – leaving treatment early due to side effects**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 06 Switching: switching to single drug (open-label data)  
 Outcome: 04 Leaving the study early due to side effects





**Next-step 06.05. Switching: single antidepressants (open-label data) – number reporting side effects**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 06 Switching: switching to single drug (open-label data)  
 Outcome: 05 Number reporting side effects



**Next-step 07. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing)**


**Next-step 07.01. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) – non-response**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 07 Augmentation: AD + AD vs AD + (placebo or nothing)  
 Outcome: 01 Number not achieving response




**Next-step 07.02. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) – non-remission**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 07 Augmentation: AD + AD vs AD + (placebo or nothing)  
 Outcome: 02 Number not achieving remission




### Next-step 07.03. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) – mean endpoint or change scores

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 07 Augmentation: AD + AD vs AD + (placebo or nothing)  
 Outcome: 03 Mean endpoint or change scores




### Next-step 07.04. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) – leaving treatment early for any reason

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 07 Augmentation: AD + AD vs AD + (placebo or nothing)  
 Outcome: 04 Leaving the study early




**Next-step 07.05. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) – leaving treatment early due to side effects**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 07 Augmentation: AD + AD vs AD + (placebo or nothing)  
 Outcome: 05 Leaving the study early due to side effects



**Next-step 07.06. Augmentation: antidepressant + antidepressant versus antidepressant + (placebo or nothing) – patients reporting side effects**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 07 Augmentation: AD + AD vs AD + (placebo or nothing)  
 Outcome: 06 Patients reporting side effects



**Next-step 08. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing)**

**Next-step 08.01. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing) – non-response**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 08 Augmentation: AD + AP vs AD + (placebo or nothing)  
 Outcome: 01 Number not achieving response






**Next-step 08.02. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing) – non-remission**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 08 Augmentation: AD + AP vs AD + (placebo or nothing)  
 Outcome: 02 Number not achieving remission




**Next-step 08.03. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing) – mean endpoint**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 08 Augmentation: AD + AP vs AD + (placebo or nothing)  
 Outcome: 03 Mean endpoint




**Next-step 08.04. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing) – number leaving treatment early for any reason**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 08 Augmentation: AD + AP vs AD + (placebo or nothing)  
 Outcome: 04 Number leaving treatment early for any reason




**Next-step 08.05. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing) – number leaving treatment early due to side effects**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 08 Augmentation: AD + AP vs AD + (placebo or nothing)  
 Outcome: 05 Number leaving treatment early due to side effects



**Next-step 08.06. Augmentation: antidepressant + antipsychotic versus antidepressant + (placebo or nothing) – number reporting side effects**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 08 Augmentation: AD + AP vs AD + (placebo or nothing)  
 Outcome: 06 Number reporting side effects



**Next-step 09. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing)**


**Next-step 09.01. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing) – non-response**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 09 Augmentation: AD + other psychotropic drug vs AD + (placebo or nothing)  
 Outcome: 01 Number not achieving response




**Next-step 09.02. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing) – non-remission**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 09 Augmentation: AD + other psychotropic drug vs AD + (placebo or nothing)  
 Outcome: 02 Number not achieving remission



**Next-step 09.03. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing) – mean endpoint change scores**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 09 Augmentation: AD + other psychotropic drug vs AD + (placebo or nothing)  
 Outcome: 03 Mean endpoint or change scores






**Next-step 09.04. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing) – leaving treatment early for any reason**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 09 Augmentation: AD + other psychotropic drug vs AD + (placebo or nothing)  
 Outcome: 04 Leaving the study early



**Next-step 09.05. Augmentation: antidepressant + other psychotropic drug versus antidepressant + (placebo or nothing) – leaving treatment early due to side effects**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 09 Augmentation: AD + other psychotropic drug vs AD + (placebo or nothing)  
 Outcome: 05 Leaving the study early due to side effects



**Next-step 10. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug - open-label data**


**Next-step 10.01. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug (open-label data) – non-remission**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 10 Augmentation: AD + other psychotropic drug vs AD + other psychotropic drug (open-label data)  
 Outcome: 01 Number not achieving remission




**Next-step 10.02. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug (open-label data) – mean endpoint (self-rated)**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 10 Augmentation: AD + other psychotropic drug vs AD + other psychotropic drug (open-label data)  
 Outcome: 02 Mean endpoint scores (self-rated)




**Next-step 10.03. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug (open-label data) – leaving treatment early for any reason**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 10 Augmentation: AD + other psychotropic drug vs AD + other psychotropic drug (open-label data)  
 Outcome: 03 Number leaving treatment early for any reason




**Next-step 10.04. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug (open-label data) – leaving treatment early due to side effects**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 10 Augmentation: AD + other psychotropic drug vs AD + other psychotropic drug (open-label data)  
 Outcome: 04 Number leaving treatment early due to side effects



**Next-step 10.05. Augmentation: antidepressant + other psychotropic drug versus antidepressant + other psychotropic drug (open-label data) – number reporting side effects**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 10 Augmentation: AD + other psychotropic drug vs AD + other psychotropic drug (open-label data)  
 Outcome: 05 Number reporting side effects



## Next-step 11. Comparisons involving CBT – open-label data

### Next-step 11.01. Switch to CBT versus single antidepressant (open-label data) – all available dichotomous data


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 11 Comparisons involving CBT (open-label data)  
 Outcome: 01 Switch to CBT or single antidepressant






**Next-step 11.02. Switch to CBT versus single antidepressant – all available continuous data**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 11 Comparisons involving CBT (open-label data)  
 Outcome: 02 Switch to CBT vs single antidepressant




**Next-step 11.03. Augmentation: antidepressant + CBT versus antidepressant + bupropion or buspirone (open-label data) – all available dichotomous data**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 11 Comparisons involving CBT (open-label data)  
 Outcome: 03 Augmentation: AD + CBT vs AD + bupripion or buspirone



**Next-step 11.04. Augmentation: antidepressant + CBT versus antidepressant + bupropion or buspirone (open-label data) – all available continuous data**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 11 Comparisons involving CBT (open-label data)  
 Outcome: 04 Augmentation: AD + CBT vs AD + bupripion or buspirone



## Next-step 12. Electroconvulsive therapy (ECT)


### Next-step 12.01. ECT: bilateral versus unilateral – all dichotomous data

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 12 Comparisons involving ECT  
 Outcome: 01 Bilateral ECT vs unilateral ECT (basic comparisons - all outcomes)




**Next-step 12.02. ECT: bilateral versus unilateral – all continuous data**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 12 Comparisons involving ECT  
 Outcome: 02 Bilateral ECT vs unilateral ECT (basic comparisons - all data)




**Next-step 12.03. ECT: bilateral versus unilateral: same dose comparison – non-response**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 12 Comparisons involving ECT  
 Outcome: 03 Bilateral ECT vs unilateral ECT (same dose) - number of non-responders




**Next-step 12.04. ECT: low-dose bilateral versus low-dose unilateral – non-response**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 12 Comparisons involving ECT  
 Outcome: 04 Low-dose bilateral ECT vs low-dose unilateral ECT - non-responders



**Next-step 12.05. ECT: low-dose bilateral versus low-dose unilateral – non-remission**


Review: Depression update: pharmacology – next-step treatments  
 Comparison: 12 Comparisons involving ECT  
 Outcome: 05 Low-dose bilateral ECT vs low-dose unilateral ECT - non-remission






**Next-step 12.06. ECT: low-dose bilateral versus low-dose unilateral – mean endpoint**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 12 Comparisons involving ECT  
 Outcome: 06 Low-dose bilateral vs low-dose unilateral - mean endpoint depression scores




### Next-step 12.07. ECT: low-dose bilateral versus high-dose unilateral – non-response

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 12 Comparisons involving ECT  
 Outcome: 07 Low-dose bilateral ECT vs high-dose unilateral ECT - non-responders




**Next-step 12.08. ECT: low-dose bilateral versus high-dose unilateral – non-remission**

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 12 Comparisons involving ECT  
 Outcome: 08 Low-dose bilateral ECT vs high-dose unilateral ECT - non-remission




### Next-step 12.09. ECT: low-dose bilateral versus high-dose unilateral – mean endpoint

Review: Depression update: pharmacology – next-step treatments  
 Comparison: 12 Comparisons involving ECT  
 Outcome: 09 Bilateral ECT (low dose) vs high-dose unilateral ECT - mean endpoint scores




## Older adults sub-analyses


Review: Pharmacology: Older adults sub-analysis  
 Comparison: 01 Amitriptyline: Overall efficacy in older adults  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 01 Amitriptyline: Overall efficacy in older adults  
 Outcome: 02 Mean endpoint scores




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 01 Amitriptyline: Overall efficacy in older adults  
 Outcome: 03 Number of inpatients not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 01 Amitriptyline: Overall efficacy in older adults  
 Outcome: 04 Mean endpoint scores in inpatients




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 01 Amitriptyline: Overall efficacy in older adults  
 Outcome: 08 Number of primary care patients not achieving at least 50% reduction in depression score



Review: Pharmacology: Older adults sub-analysis  
 Comparison: 01 Amitriptyline: Overall efficacy in older adults  
 Outcome: 09 Mean endpoint scores in primary care patients




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 02 Amitriptyline: Overall tolerability in older adults  
 Outcome: 01 Leaving the study early







Review: Pharmacology: Older adults sub-analysis  
 Comparison: 02 Amitriptyline: Overall tolerability in older adults  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 02 Amitriptyline: Overall tolerability in older adults  
 Outcome: 03 Patients with side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 02 Amitriptyline: Overall tolerability in older adults  
 Outcome: 04 Leaving the study early in inpatients




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 02 Amitriptyline: Overall tolerability in older adults  
 Outcome: 05 Leaving the study early due to side effects in inpatients




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 02 Amitriptyline: Overall tolerability in older adults  
 Outcome: 06 Inpatients with side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 02 Amitriptyline: Overall tolerability in older adults  
 Outcome: 07 Leaving the study early in outpatients




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 02 Amitriptyline: Overall tolerability in older adults  
 Outcome: 08 Leaving the study early due to side effects in outpatients




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 02 Amitriptyline: Overall tolerability in older adults  
 Outcome: 10 Leaving the study early in primary care patients




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 02 Amitriptyline: Overall tolerability in older adults  
 Outcome: 11 Leaving the study early due to side effects in primary care patients




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 02 Amitriptyline: Overall tolerability in older adults  
 Outcome: 12 Patients in primary care with side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 03 SSRIs versus alternative antidepressants in older adults  
 Outcome: 01 Mean endpoint scores




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 03 SSRIs versus alternative antidepressants in older adults  
 Outcome: 02 Mean endpoint scores in Inpatients



Review: Pharmacology: Older adults sub-analysis  
 Comparison: 03 SSRIs versus alternative antidepressants in older adults  
 Outcome: 03 Mean endpoint scores outpatients




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 03 SSRIs versus alternative antidepressants in older adults  
 Outcome: 04 Mean endpoint scores in Primary Care







Review: Pharmacology: Older adults sub-analysis  
 Comparison: 03 SSRIs versus alternative antidepressants in older adults  
 Outcome: 05 Leaving the study early




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 03 SSRIs versus alternative antidepressants in older adults  
 Outcome: 06 Leaving the study due to side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 03 SSRIs versus alternative antidepressants in older adults  
 Outcome: 07 Patients reporting adverse events




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 04 Venlafaxine: Efficacy in older adults  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 04 Venlafaxine: Efficacy in older adults  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 05 Venlafaxine: Tolerability in older adults  
 Outcome: 01 Leaving the study early



Review: Pharmacology: Older adults sub-analysis  
 Comparison: 05 Venlafaxine: Tolerability in older adults  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 05 Venlafaxine: Tolerability in older adults  
 Outcome: 03 Patients reporting side effects







Review: Pharmacology: Older adults sub-analysis  
 Comparison: 06 Mirtazapine: Overall efficacy in older adults  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 06 Mirtazapine: Overall efficacy in older adults  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 06 Mirtazapine: Overall efficacy in older adults  
 Outcome: 03 Mean end point scores




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 07 Mirtazapine: Overall tolerability in older adults  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 07 Mirtazapine: Overall tolerability in older adults  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 07 Mirtazapine: Overall tolerability in older adults  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 08 Phenelzine: Overall efficacy in older adults  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 09 Phenelzine: Overall tolerability in older adults  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 09 Phenelzine: Overall tolerability in older adults  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 09 Phenelzine: Overall tolerability in older adults  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 10 TCAs against alternative antidepressants: Efficacy in older adults  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 10 TCAs against alternative antidepressants: Efficacy in older adults  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 10 TCAs against alternative antidepressants: Efficacy in older adults  
 Outcome: 03 Mean endpoint scores



Review: Pharmacology: Older adults sub-analysis  
 Comparison: 10 TCAs against alternative antidepressants: Efficacy in older adults  
 Outcome: 05 Mean endpoint scores in inpatients




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 10 TCAs against alternative antidepressants: Efficacy in older adults  
 Outcome: 07 Number of outpatients not achieving remission







Review: Pharmacology: Older adults sub-analysis  
 Comparison: 10 TCAs against alternative antidepressants: Efficacy in older adults  
 Outcome: 09 Mean endpoint scores in outpatients




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 11 TCAs against alternative antidepressants: Tolerability in older adults  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 11 TCAs against alternative antidepressants: Tolerability in older adults  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 11 TCAs against alternative antidepressants: Tolerability in older adults  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 12 Lithium augmentation: Overall efficacy in older adults  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 13 Lithium augmentation: Overall tolerability in older adults  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 13 Lithium augmentation: Overall tolerability in older adults  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 14 St John's wort: Efficacy in older adults  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 14 St John's wort: Efficacy in older adults  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 15 St John's wort: Tolerability in older adults  
 Outcome: 01 Leaving the study early



Review: Pharmacology: Older adults sub-analysis  
 Comparison: 15 St John's wort: Tolerability in older adults  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 15 St John's wort: Tolerability in older adults  
 Outcome: 03 Patients reporting side effects







Review: Pharmacology: Older adults sub-analysis  
 Comparison: 16 Relapse prevention for older adults  
 Outcome: 01 Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 16 Relapse prevention for older adults  
 Outcome: 02 Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 16 Relapse prevention for older adults  
 Outcome: 03 Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 16 Relapse prevention for older adults  
 Outcome: 04 SSRIs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 16 Relapse prevention for older adults  
 Outcome: 05 SSRIs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 16 Relapse prevention for older adults  
 Outcome: 06 SSRIs: Number of patients with relapse of depression (2x2 analysis)



Review: Pharmacology: Older adults sub-analysis  
 Comparison: 16 Relapse prevention for older adults  
 Outcome: 07 TCAs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 16 Relapse prevention for older adults  
 Outcome: 08 TCAs: Number of patients with relapse of depression (by randomised study time)







Review: Pharmacology: Older adults sub-analysis  
 Comparison: 16 Relapse prevention for older adults  
 Outcome: 09 TCAs: Number of patients with relapse of depression (2x2 analysis)



Review: Pharmacology: Older adults sub-analysis  
 Comparison: 17 Antidepressant + antipsychotic vs control in older adults  
 Outcome: 01 Number of people not achieving remission




Review: Pharmacology: Older adults sub-analysis  
 Comparison: 17 Antidepressant + antipsychotic vs control in older adults  
 Outcome: 02 Mean endpoint scores




# Phenelzine


Review: Pharmacology: Phenelzine  
 Comparison: 01 Overall efficacy  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Phenelzine  
 Comparison: 01 Overall efficacy  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Phenelzine  
 Comparison: 01 Overall efficacy  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Phenelzine  
 Comparison: 02 Overall tolerability  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Phenzelzine  
 Comparison: 02 Overall tolerability  
 Outcome: 02 Leaving the study early due to side effects



Review: Pharmacology: Phenelzine  
 Comparison: 02 Overall tolerability  
 Outcome: 03 Patients reporting adverse effects




Review: Pharmacology: Phenelzine  
 Comparison: 03 Overall efficacy against SSRIs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score







Review: Pharmacology: Phenelzine  
 Comparison: 03 Overall efficacy against SSRIs  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Phenelzine  
 Comparison: 03 Overall efficacy against SSRIs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Phenelzine  
 Comparison: 04 Overall tolerability against SSRIs  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Phenelzine  
 Comparison: 04 Overall tolerability against SSRIs  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Phenelzine  
 Comparison: 05 Overall efficacy against TCAs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Phenelzine  
 Comparison: 05 Overall efficacy against TCAs  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Phenzelzine  
 Comparison: 05 Overall efficacy against TCAs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Phenezine  
 Comparison: 06 Overall tolerability against TCAs  
 Outcome: 01 Leaving the study early



Review: Pharmacology: Phenelzine  
 Comparison: 06 Overall tolerability against TCAs  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Phenelzine  
 Comparison: 06 Overall tolerability against TCAs  
 Outcome: 03 Patients reporting adverse effects




## Depression with psychotic features

Review: Pharmacology. Psychotic depression  
 Comparison: 01 Antidepressant + antipsychotic vs control (<15% bipolar patients)  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score







Review: Pharmacology: Psychotic depression  
 Comparison: 01 Antidepressant + antipsychotic vs control (<15% bipolar patients)  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Psychotic depression  
 Comparison: 01 Antidepressant + antipsychotic vs control (<15% bipolar patients)  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Psychotic depression  
 Comparison: 01 Antidepressant + antipsychotic vs control (<15% bipolar patients)  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Psychotic depression  
 Comparison: 02 Antidepressant vs antidepressant (<15% bipolar patients)  
 Outcome: 01 Number of people not achieving remission




Review: Pharmacology: Psychotic depression  
 Comparison: 02 Antidepressant vs antidepressant (<15% bipolar patients)  
 Outcome: 02 Leaving the study early




Review: Pharmacology: Psychotic depression  
 Comparison: 02 Antidepressant vs antidepressant (<15% bipolar patients)  
 Outcome: 03 Leaving the study early due to side effects




Review: Pharmacology: Psychotic depression  
 Comparison: 03 Antidepressant + antipsychotic vs control (<25% bipolar patients)  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Psychotic depression  
 Comparison: 03 Antidepressant + antipsychotic vs control (<25% bipolar patients)  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Psychotic depression  
 Comparison: 03 Antidepressant + antipsychotic vs control (<25% bipolar patients)  
 Outcome: 03 Mean endpoint scores



Review: Pharmacology: Psychotic depression  
 Comparison: 03 Antidepressant + antipsychotic vs control (<25% bipolar patients)  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Psychotic depression  
 Comparison: 04 Antidepressant vs antidepressant (<25% bipolar patients)  
 Outcome: 01 Number of people not achieving remission






Review: Pharmacology: Psychotic depression  
 Comparison: 04 Antidepressant vs antidepressant (<25% bipolar patients)  
 Outcome: 02 Leaving the study early




Review: Pharmacology: Psychotic depression  
 Comparison: 04 Antidepressant vs antidepressant (<25% bipolar patients)  
 Outcome: 03 Leaving the study early due to side effects




# Reboxetine


Review: Pharmacology: Reboxetine  
 Comparison: 01 Efficacy against other ADs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Reboxetine  
 Comparison: 01 Efficacy against other ADs  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Reboxetine  
 Comparison: 01 Efficacy against other ADs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Reboxetine  
 Comparison: 02 Tolerability against other ADs  
 Outcome: 01 Leaving the study early




Review: Pharmacology: Reboxetine  
 Comparison: 02 Tolerability against other ADs  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Reboxetine  
 Comparison: 02 Tolerability against other ADs  
 Outcome: 03 Patients reporting side effects



Review: Pharmacology: Reboxetine  
 Comparison: 03 Efficacy against placebo  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Reboxetine  
 Comparison: 03 Efficacy against placebo  
 Outcome: 02 Number of people not achieving remission







Review: Pharmacology: Reboxetine  
 Comparison: 04 Tolerability against placebo  
 Outcome: 01 Leaving the study early



Review: Pharmacology: Reboxetine  
 Comparison: 04 Tolerability against placebo  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: Reboxetine  
 Comparison: 04 Tolerability against placebo  
 Outcome: 03 Patients reporting side effects




## Relapse prevention

Review: Pharmacology: Relapse prevention  
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 01 Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention  
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 02 Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention  
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 03 Number of patients with relapse of depression (2x2 analysis)

Study or sub-category	Treatment n/N	Control n/N	RD (random) 95% CI	Weight %	RD (random) 95% CI	Order
<b>01 &lt;6 months treatment prior to randomisation / &lt;12 months of randomised treatment</b>						
Doogan1992 Y O C	12/185	33/110		4.56	-0.24 [-0.33, -0.14]	0
Feiger1999 Y O C	1/65	9/66		4.68	-0.12 [-0.21, -0.03]	0
GORWOOD2007 E O	13/152	50/153		4.71	-0.24 [-0.33, -0.15]	0
Hochstrasser2001 YMC	24/132	59/137		4.22	-0.25 [-0.35, -0.14]	0
Klysner2002 E O C	19/60	41/61		2.88	-0.36 [-0.52, -0.19]	0
Montgomery1992 Y M C	11/105	13/42		3.17	-0.20 [-0.36, -0.05]	0
PERAHIA2006B Y O	62/136	95/142		4.02	-0.21 [-0.33, -0.10]	0
RAPAPORT2004 Y ?	31/181	22/93		4.31	-0.07 [-0.17, 0.04]	0
Robert1995 Y O C	21/152	18/74		4.06	-0.11 [-0.22, 0.01]	0
Robinson1991 Y O C	9/31	13/16		1.73	-0.52 [-0.77, -0.27]	0
Sackeim2001 Y ? S	15/27	21/29		1.74	-0.17 [-0.42, 0.08]	0
Schmidt2000 Y O C	49/189	61/122		4.15	-0.24 [-0.35, -0.13]	0
Thase2001 Y ? C	15/77	34/84		3.47	-0.21 [-0.35, -0.07]	0
VANdenBROEK2006 YI	2/12	12/15		1.36	-0.63 [-0.93, -0.34]	0
Versiani1999 Y M C	29/145	74/141		4.24	-0.32 [-0.43, -0.22]	0
<b>Subtotal (95% CI)</b>	<b>1649</b>	<b>1285</b>		<b>53.29</b>	<b>-0.23 [-0.28, -0.18]</b>	
Total events: 313 (Treatment), 555 (Control)						
Test for heterogeneity: Chi <sup>2</sup> = 38.67, df = 14 (P = 0.0004), I <sup>2</sup> = 63.8%						
Test for overall effect: Z = 8.40 (P < 0.00001)						
<b>02 &lt;6 months treatment prior to randomisation / &gt;=12 months of randomised treatment</b>						
Alexopoulos2000 EOC	4/22	11/21		1.56	-0.34 [-0.61, -0.07]	0
Kishimoto1994 Y O S	4/12	13/14		1.32	-0.60 [-0.89, -0.30]	0
MCGRATH2006 Y ?	60/131	94/131		3.99	-0.26 [-0.37, -0.14]	0
Montgomery1988 ? O C	23/108	54/112		3.86	-0.27 [-0.39, -0.15]	0
Montgomery1993 Y M C	10/68	27/67		3.31	-0.26 [-0.40, -0.11]	0
Prien1984 Y M S	13/40	22/34		2.10	-0.32 [-0.54, -0.11]	0
Terra1998 Y O C	14/110	33/94		4.00	-0.22 [-0.34, -0.11]	0
<b>Subtotal (95% CI)</b>	<b>491</b>	<b>473</b>		<b>20.13</b>	<b>-0.27 [-0.33, -0.22]</b>	
Total events: 128 (Treatment), 254 (Control)						
Test for heterogeneity: Chi <sup>2</sup> = 5.73, df = 6 (P = 0.45), I <sup>2</sup> = 0%						
Test for overall effect: Z = 9.47 (P < 0.00001)						
<b>03 &gt;=6 months treatment prior to randomisation / &lt;12 months of randomised treatment</b>						
Cook1986 E O C	0/7	3/9		1.07	-0.33 [-0.67, 0.01]	0
Gilaberte2001 Y O C	14/70	28/70		3.24	-0.20 [-0.35, -0.05]	0
<b>Subtotal (95% CI)</b>	<b>77</b>	<b>79</b>		<b>4.31</b>	<b>-0.22 [-0.36, -0.09]</b>	
Total events: 14 (Treatment), 31 (Control)						
Test for heterogeneity: Chi <sup>2</sup> = 0.51, df = 1 (P = 0.48), I <sup>2</sup> = 0%						
Test for overall effect: Z = 3.19 (P = 0.001)						
<b>04 &gt;=6 months treatment prior to randomisation / &gt;=12 months of randomised treatment</b>						
Frank1990 Y O C	12/53	35/49		2.82	-0.49 [-0.66, -0.32]	0
Georgotas1989 E O C	9/29	15/23		1.65	-0.34 [-0.60, -0.08]	0
KORNSTEIN2006A Y ?	20/73	43/66		3.12	-0.38 [-0.53, -0.22]	0
Keller1998 Y O C	5/77	19/84		4.24	-0.16 [-0.27, -0.06]	0
Kupfer1992 Y O C	1/11	6/9		1.01	-0.58 [-0.93, -0.22]	0
PREVENT study A Y O	30/129	54/129		4.06	-0.19 [-0.30, -0.07]	0
PREVENT study B Y O	3/43	18/40		2.78	-0.38 [-0.55, -0.21]	0
Wilson2003 E P C	25/56	31/57		2.58	-0.10 [-0.28, 0.09]	0
<b>Subtotal (95% CI)</b>	<b>471</b>	<b>457</b>		<b>22.27</b>	<b>-0.30 [-0.41, -0.19]</b>	
Total events: 105 (Treatment), 221 (Control)						
Test for heterogeneity: Chi <sup>2</sup> = 22.64, df = 7 (P = 0.002), I <sup>2</sup> = 69.1%						
Test for overall effect: Z = 5.57 (P < 0.00001)						
<b>Total (95% CI)</b>	<b>2688</b>	<b>2294</b>		<b>100.00</b>	<b>-0.25 [-0.29, -0.22]</b>	
Total events: 560 (Treatment), 1061 (Control)						
Test for heterogeneity: Chi <sup>2</sup> = 72.00, df = 31 (P < 0.0001), I <sup>2</sup> = 56.9%						

Review: Pharmacology; Relapse prevention  
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 04 SSRIs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention  
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 05 SSRIs: Number of patients with relapse of depression (by randomised study time)







Review: Pharmacology: Relapse prevention  
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 06 SSRIs: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention  
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 07 TCAs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention  
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 08 TCAs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention  
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 09 TCAs: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention  
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 10 Venlafaxine or duloxetine: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention  
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 11 Venlafaxine or duloxetine: Number of patients with relapse of depression (by randomised study time)



Review: Pharmacology: Relapse prevention  
 Comparison: 01 Responders randomised to maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 12 Venlafaxine or duloxetine: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention  
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)  
 Outcome: 01 Number of patients with relapse of depression (by pre-randomisation treatment)







Review: Pharmacology: Relapse prevention  
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)  
 Outcome: 02 Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention  
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)  
 Outcome: 03 Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention  
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)  
 Outcome: 04 SSRIs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention  
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)  
 Outcome: 05 SSRIs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention  
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)  
 Outcome: 06 SSRIs: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention  
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)  
 Outcome: 07 TCAs: Number of patients with relapse of depression (by pre-randomisation treatment)



Review: Pharmacology: Relapse prevention  
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)  
 Outcome: 08 TCAs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention  
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)  
 Outcome: 09 TCAs: Number of patients with relapse of depression (2x2 analysis)







Review: Pharmacology: Relapse prevention  
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)  
 Outcome: 10 Venlafaxine or duloxetine: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention  
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)  
 Outcome: 11 Venlafaxine or duloxetine: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention  
 Comparison: 02 Responders randomised to maintenance treatment or placebo following same acute treatment (2x2 time analyses)  
 Outcome: 12 Venlafaxine or duloxetine: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention  
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)  
 Outcome: 01 Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention  
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)  
 Outcome: 02 Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention  
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)  
 Outcome: 03 Number of patients with relapse of depression (2x2 analysis)



Review: Pharmacology: Relapse prevention  
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)  
 Outcome: 04 SSRIs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention  
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)  
 Outcome: 05 SSRIs: Number of patients with relapse of depression (by randomised study time)







Review: Pharmacology: Relapse prevention  
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)  
 Outcome: 06 SSRIs: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention  
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)  
 Outcome: 07 TCAs: Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention  
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)  
 Outcome: 08 TCAs: Number of patients with relapse of depression (by randomised study time)




Review: Pharmacology: Relapse prevention  
 Comparison: 03 Responders randomised to maintenance treatment or placebo following different acute treatment (2x2 analyses)  
 Outcome: 09 TCAs: Number of patients with relapse of depression (2x2 analysis)




Review: Pharmacology: Relapse prevention  
 Comparison: 04 Responders randomised to maintenance treatment or placebo (2x2 time analyses by previous episodes)  
 Outcome: 01 Number of patients with relapse of depression (by pre-randomisation treatment): at least 1 previous episode




Review: Pharmacology: Relapse prevention  
 Comparison: 04 Responders randomised to maintenance treatment or placebo (2x2 time analyses by previous episodes)  
 Outcome: 02 Number of patients with relapse of depression (by randomised study time): at least one previous episode



Review: Pharmacology: Relapse prevention  
 Comparison: 04 Responders randomised to maintenance treatment or placebo (2x2 time analyses by previous episodes)  
 Outcome: 03 Number of patients with relapse of depression (2x2 analysis): at least one previous episode




Review: Pharmacology: Relapse prevention  
 Comparison: 04 Responders randomised to maintenance treatment or placebo (2x2 time analyses by previous episodes)  
 Outcome: 04 Number of patients with relapse of depression (by pre-randomisation treatment): first episode







Review: Pharmacology: Relapse prevention  
 Comparison: 04 Responders randomised to maintenance treatment or placebo (2x2 time analyses by previous episodes)  
 Outcome: 05 Number of patients with relapse of depression (by randomised study time): first episode




Review: Pharmacology: Relapse prevention  
 Comparison: 04 Responders randomised to maintenance treatment or placebo (2x2 time analyses by previous episodes)  
 Outcome: 06 Number of patients with relapse of depression (2x2 analysis): first episode




Review: Pharmacology: Relapse prevention  
 Comparison: 05 Responders randomised to lithium maintenance treatment or placebo (2x2 time analyses)  
 Outcome: 01 Number of patients with relapse of depression (by pre-randomisation treatment)




Review: Pharmacology: Relapse prevention  
 Comparison: 06 Responders randomised to maintenance treatment or placebo  
 Outcome: 01 Number of patients with relapse of depression (by length of time in remission)




Review: Pharmacology: Relapse prevention  
 Comparison: 06 Responders randomised to maintenance treatment or placebo  
 Outcome: 02 Number of patients with relapse of depression (by length of time in remission/length of randomised treatment)




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 01 Relapses during 1st month of randomised treatment



Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 02 Relapses during 2nd month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 03 Relapses during 3rd month of randomised treatment







Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 04 Relapses during 4th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 05 Relapses during 5th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 06 Relapses during 6th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 07 Relapses during 7th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 08 Relapses during 8th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 09 Relapses during 9th month of randomised treatment



Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 10 Relapses during 10th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 11 Relapses during 11th month of randomised treatment







Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 12 Relapses during 12th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 13 Relapses during 13th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 14 Relapses during 14th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 15 Relapses during 15th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 16 Relapses during 16th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 17 Relapses during 17th month of randomised treatment



Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 18 Relapses during 18th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 19 Relapses during 19th month of randomised treatment







Review: Pharmacology: Relapse prevention  
 Comparison: 07 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 20 Relapses during and after 20th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 01 Relapses during 1st month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 02 Relapses during 2nd month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 03 Relapses during 3rd month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 04 Relapses during 4th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 05 Relapses during 5th month of randomised treatment



Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 06 Relapses during 6th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 07 Relapses during 7th month of randomised treatment







Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 08 Relapses during 8th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 09 Relapses during 9th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 10 Relapses during 10th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 11 Relapses during 11th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 12 Relapses during 12th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 13 Relapses during 13th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 14 Relapses during 14th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 15 Relapses during 15th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 16 Relapses during 16th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 17 Relapses during 17th month of randomised treatment



Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 18 Relapses during 18th month of randomised treatment




Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 19 Relapses during 19th month of randomised treatment







Review: Pharmacology: Relapse prevention  
 Comparison: 08 Responders randomised to maintenance treatment or placebo: time analysis  
 Outcome: 20 Relapses during and after 20th month of randomised treatment



Review: Pharmacology: Relapse prevention  
 Comparison: 09 Responders randomised to continue augmentation treatment or placebo (maintained on antidepressant)  
 Outcome: 01 Number of patients with relapse (risperidone + citalopram vs placebo + citalopram)




Review: Pharmacology: Relapse prevention  
 Comparison: 10 Responders to ECT randomised to continuation treatments  
 Outcome: 01 Number of patients with relapse




# SSRIs versus antidepressants


Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 01 Overall Efficacy




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 02 Efficacy in In-patients




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 03 Efficacy in Out-patients




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 04 Efficacy in Primary Care




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 05 Leaving the study early



Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 06 Inpatients leaving the study early




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 07 Outpatients leaving the study yearly







Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 08 Primary care patients leaving the study early




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 09 Leaving the study due to side effects




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 10 Inpatients leaving the study due to side effects




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 11 Outpatients leaving the study due to side effects




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 12 Primary care patients leaving the study due to side effects




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 13 Patients reporting adverse events



Review: Pharmacology. SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 14 Inpatients reporting adverse events




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 15 Outpatients reporting adverse events







Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 01 SSRIs versus alternative antidepressants  
 Outcome: 16 Primary care patients reporting adverse events




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 01 Overall Efficacy




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 02 Efficacy in In-patients




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 03 Efficacy in Out-patients




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 04 Efficacy in Primary Care




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 05 Leaving the study early (v TCAs)



Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 06 Inpatients leaving the study early (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 07 Outpatients leaving the study early (v TCAs)







Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 08 Primary care patients leaving the study early (vTCAAs)




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 09 Leaving the study due to side effects (v TCAs)




Review: Pharmacology. SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 10 Inpatients leaving the study due to side effects (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 11 Outpatients leaving the study due to side effects (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 12 Primary care patients leaving the study due to side effects (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 13 Patients reporting adverse events (vTCAs)



Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 14 Inpatients reporting adverse events (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 15 Outpatients reporting adverse events (v TCAs)







Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 02 SSRIs versus tricyclic antidepressants  
 Outcome: 16 Primary care patients reporting adverse events (v TCAs)




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 03 SSRIs versus 3rd generation ADs  
 Outcome: 01 Overall Efficacy




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 03 SSRIs versus 3rd generation ADs  
 Outcome: 02 Efficacy in In-patients




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 03 SSRIs versus 3rd generation ADs  
 Outcome: 03 Efficacy in Out-patients




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 03 SSRIs versus 3rd generation ADs  
 Outcome: 04 Efficacy in Primary Care patients




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 03 SSRIs versus 3rd generation ADs  
 Outcome: 05 Leaving the study early



Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 03 SSRIs versus 3rd generation ADs  
 Outcome: 06 Leaving the study due to side effects




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 03 SSRIs versus 3rd generation ADs  
 Outcome: 07 Patients reporting adverse events







Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 04 SSRIs versus (venlafaxine or mirtazapine)  
 Outcome: 01 Overall Efficacy




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 04 SSRIs versus (venlafaxine or mirtazapine)  
 Outcome: 02 Efficacy in In-patients




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 04 SSRIs versus (venlafaxine or mirtazapine)  
 Outcome: 03 Efficacy in Out-patients




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 04 SSRIs versus (venlafaxine or mirtazapine)  
 Outcome: 04 Efficacy in Primary Care patients




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 05 SSRIs versus MAOIs  
 Outcome: 01 Overall Efficacy



Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 05 SSRIs versus MAOIs  
 Outcome: 02 Efficacy in In-patients




Review: Pharmacology: SSRIs versus antidepressants  
 Comparison: 05 SSRIs versus MAOIs  
 Outcome: 03 Efficacy in Out-patients




# SSRIs versus placebo

Review: Pharmacology: SSRIs versus placebo  
 Comparison: 01 Overall efficacy  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 01 Overall efficacy  
 Outcome: 02 Number of people not achieving remission







Review: Pharmacology: SSRIs versus placebo  
 Comparison: 01 Overall efficacy  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 02 Overall Tolerability  
 Outcome: 01 Leaving the study early




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 02 Overall Tolerability  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 02 Overall Tolerability  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 02 Overall Tolerability  
 Outcome: 04 Sensitivity analysis: Leaving the study early




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 03 Overall efficacy by severity  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 03 Overall efficacy by severity  
 Outcome: 02 Number of people not achieving remission



Review: Pharmacology: SSRIs versus placebo  
 Comparison: 03 Overall efficacy by severity  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 04 Overall Tolerability: trials >=8 weeks long  
 Outcome: 01 Leaving the study early







Review: Pharmacology: SSRIs versus placebo  
 Comparison: 04 Overall Tolerability: trials >=8 weeks long  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 04 Overall Tolerability: trials >=8 weeks long  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 05 Overall efficacy: trials >=8 weeks long  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 05 Overall efficacy: trials >=8 weeks long  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 05 Overall efficacy: trials >=8 weeks long  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 06 Overall efficacy by severity: trials >=8 weeks long  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score



Review: Pharmacology: SSRIs versus placebo  
 Comparison: 06 Overall efficacy by severity: trials >=8 weeks long  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: SSRIs versus placebo  
 Comparison: 06 Overall efficacy by severity: trials >=8 weeks long  
 Outcome: 03 Mean endpoint scores




# St John's wort

Review: Pharmacology: St John's wort  
 Comparison: 01 Efficacy against ADs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology. St John's wort  
 Comparison: 01 Efficacy against ADs  
 Outcome: 02 Number of people not achieving remission







Review: Pharmacology: St John's wort  
 Comparison: 01 Efficacy against ADs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: St John's wort  
 Comparison: 02 Tolerability against ADs  
 Outcome: 01 Leaving the study early




Review: Pharmacology: St John's wort  
 Comparison: 02 Tolerability against ADs  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: St John's wort  
 Comparison: 02 Tolerability against ADs  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: St John's wort  
 Comparison: 03 Efficacy against SSRIs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: St John's wort  
 Comparison: 03 Efficacy against SSRIs  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: St John's wort  
 Comparison: 03 Efficacy against SSRIs  
 Outcome: 03 Mean endpoint scores



Review: Pharmacology: St John's wort  
 Comparison: 04 Tolerability against SSRIs  
 Outcome: 01 Leaving the study early




Review: Pharmacology: St John's wort  
 Comparison: 04 Tolerability against SSRIs  
 Outcome: 02 Leaving the study early due to side effects







Review: Pharmacology: St John's wort  
 Comparison: 04 Tolerability against SSRIs  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: St John's wort  
 Comparison: 05 Efficacy against TCAs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: St John's wort  
 Comparison: 05 Efficacy against TCAs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: St John's wort  
 Comparison: 06 Tolerability against TCAs  
 Outcome: 01 Leaving the study early




Review: Pharmacology: St John's wort  
 Comparison: 06 Tolerability against TCAs  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: St John's wort  
 Comparison: 06 Tolerability against TCAs  
 Outcome: 03 Patients reporting side effects



Review: Pharmacology: St John's wort  
 Comparison: 07 Efficacy against therapeutic doses of ADs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: St John's wort  
 Comparison: 07 Efficacy against therapeutic doses of ADs  
 Outcome: 03 Mean endpoint scores







Review: Pharmacology: St John's wort  
 Comparison: 08 Efficacy against low doses of ADs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: St John's wort  
 Comparison: 08 Efficacy against low doses of ADs  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: St John's wort  
 Comparison: 08 Efficacy against low doses of ADs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: St John's wort  
 Comparison: 09 Tolerability against therapeutic doses of ADs  
 Outcome: 01 Leaving the study early




Review: Pharmacology: St John's wort  
 Comparison: 09 Tolerability against therapeutic doses of ADs  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: St John's wort  
 Comparison: 09 Tolerability against therapeutic doses of ADs  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: St John's wort  
 Comparison: 10 Tolerability against low doses of ADs  
 Outcome: 01 Leaving the study early



Review: Pharmacology: St John's wort  
 Comparison: 10 Tolerability against low doses of ADs  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: St John's wort  
 Comparison: 10 Tolerability against low doses of ADs  
 Outcome: 03 Patients reporting side effects







Review: Pharmacology: St John's wort  
 Comparison: 11 Efficacy against ADs by severity of depression  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: St John's wort  
 Comparison: 11 Efficacy against ADs by severity of depression  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: St John's wort  
 Comparison: 11 Efficacy against ADs by severity of depression  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: St John's wort  
 Comparison: 12 Therapeutic dose / severity  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score / moderate depression




Review: Pharmacology: St John's wort  
 Comparison: 12 Therapeutic dose / severity  
 Outcome: 02 Number of people not achieving at least 50% reduction in depression score / severe depression




Review: Pharmacology: St John's wort  
 Comparison: 12 Therapeutic dose / severity  
 Outcome: 03 Mean endpoint scores / moderate depression




Review: Pharmacology: St John's wort  
 Comparison: 12 Therapeutic dose / severity  
 Outcome: 04 Mean endpoint scores / severe depression



Review: Pharmacology. St John's wort  
 Comparison: 13 Low dose / severity  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score / moderate depression




Review: Pharmacology: St John's wort  
 Comparison: 13 Low dose / severity  
 Outcome: 02 Number of people not achieving at least 50% reduction in depression score / severe depression







Review: Pharmacology: St John's wort  
 Comparison: 13 Low dose / severity  
 Outcome: 03 Number of people not achieving remission / severe depression




Review: Pharmacology: St John's wort  
 Comparison: 13 Low dose / severity  
 Outcome: 04 Mean endpoint scores / moderate depression




Review: Pharmacology: St John's wort  
 Comparison: 13 Low dose / severity  
 Outcome: 05 Mean endpoint scores / severe depression




Review: Pharmacology: St John's wort  
 Comparison: 14 Efficacy against placebo  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: St John's wort  
 Comparison: 14 Efficacy against placebo  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: St John's wort  
 Comparison: 14 Efficacy against placebo  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: St John's wort  
 Comparison: 14 Efficacy against placebo  
 Outcome: 04 Sensitivity analysis: Number of people not achieving at least 50% reduction in depression score




Review: Phamacology: St John's wort  
 Comparison: 14 Efficacy against placebo  
 Outcome: 05 Sensitivity analysis: Mean endpoint scores




Review: Pharmacology: St John's wort  
 Comparison: 14 Efficacy against placebo  
 Outcome: 06 Mean endpoint scores (HRSD-17 only)




Review: Pharmacology: St John's wort  
 Comparison: 15 Tolerability against placebo  
 Outcome: 01 Leaving the study early




Review: Pharmacology: St John's wort  
 Comparison: 15 Tolerability against placebo  
 Outcome: 02 Leaving the study early due to side effects




Review: Pharmacology: St John's wort  
 Comparison: 15 Tolerability against placebo  
 Outcome: 03 Patients reporting side effects




Review: Pharmacology: St John's wort  
 Comparison: 16 Efficacy against placebo by severity  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score



Review: Pharmacology: St John's wort  
 Comparison: 16 Efficacy against placebo by severity  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: St John's wort  
 Comparison: 16 Efficacy against placebo by severity  
 Outcome: 03 Mean endpoint scores







Review: Pharmacology: St John's wort  
 Comparison: 16 Efficacy against placebo by severity  
 Outcome: 04 Sensitivity analysis: Number of people not achieving at least 50% reduction in depression score



Review: Pharmacology: St John's wort  
 Comparison: 16 Efficacy against placebo by severity  
 Outcome: 05 Sensitivity analysis: Mean endpoint scores



Review: Pharmacology: St John's wort  
 Comparison: 16 Efficacy against placebo by severity  
 Outcome: 06 Sensitivity analysis: Mean endpoint scores




# TCAs versus placebo

## TCA.01. TCAs versus placebo – efficacy data


### TCA.01.01. Mean endpoint depression scores

Review: Depression update: pharmacology TCAs vs placebo  
 Comparison: 01 Efficacy data  
 Outcome: 01 Mean endpoint depression scores




## TCA.01.02. Mean depression change scores

Review: Depression update: pharmacology TCAs vs placebo  
 Comparison: 01 Efficacy data  
 Outcome: 02 Mean depression change scores




### TCA.01.03. Mean depression change scores (sensitivity analysis)

Review: Depression update: pharmacology TCAs vs placebo  
 Comparison: 01 Efficacy data  
 Outcome: 03 Sensitivity analysis: Mean depression change scores




## TCA.01.04. Non-remission data

Review: Depression update: pharmacology TCAs vs placebo  
 Comparison: 01 Efficacy data  
 Outcome: 04 Number not achieving remission




## TCA.01.05. Non-response data

Review: Depression update: pharmacology TCAs vs placebo  
 Comparison: 01 Efficacy data  
 Outcome: 05 Number not achieving response (50% reduction in depression scores)



## TCA.01.06. Non-response data (sensitivity analysis)

Review: Depression update: pharmacology TCAs vs placebo  
 Comparison: 01 Efficacy data  
 Outcome: 06 Sensitivity analysis: Number not achieving response (50% reduction in depression scores)






# TCA.02. TCAs versus placebo - acceptability and tolerability data


## TCA.02.01. Number leaving treatment early for any reason

Review: Depression update: pharmacology TCAs vs placebo  
 Comparison: 02 Acceptability and tolerability data  
 Outcome: 01 Number leaving treatment early for any reason




## TCA.02.02. Number leaving treatment early due to side effects

Review: Depression update: pharmacology TCAs vs placebo  
 Comparison: 02 Acceptability and tolerability data  
 Outcome: 02 Number leaving treatment early due to side effects




## TCA.02.03. Number reporting side effects

Review: Depression update: pharmacology TCAs vs placebo  
 Comparison: 02 Acceptability and tolerability data  
 Outcome: 03 Number reporting side effects




# Venlafaxine


Review: Pharmacology: Venlafaxine  
 Comparison: 01 Venlafaxine versus other antidepressants  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 01 Venlafaxine versus other antidepressants  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 01 Venlafaxine versus other antidepressants  
 Outcome: 03 Mean endpoint scores



Review: Pharmacology: Venlafaxine  
 Comparison: 01 Venlafaxine versus other antidepressants  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 01 Venlafaxine versus other antidepressants  
 Outcome: 05 Leaving the study early due to side effects







Review: Pharmacology: Venlafaxine  
 Comparison: 01 Venlafaxine versus other antidepressants  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 02 Venlafaxine versus TCAs and SSRIs (not mirtazapine)  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 02 Venlafaxine versus TCAs and SSRIs (not mirtazapine)  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 02 Venlafaxine versus TCAs and SSRIs (not mirtazapine)  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 02 Venlafaxine versus TCAs and SSRIs (not mirtazapine)  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 02 Venlafaxine versus TCAs and SSRIs (not mirtazapine)  
 Outcome: 05 Leaving the study early due to side effects



Review: Pharmacology: Venlafaxine  
 Comparison: 02 Venlafaxine versus TCAs and SSRIs (not mirtazapine)  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 03 Venlafaxine versus SSRIs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score







Review: Pharmacology: Venlafaxine  
 Comparison: 03 Venlafaxine versus SSRIs  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 03 Venlafaxine versus SSRIs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 03 Venlafaxine versus SSRIs  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 03 Venlafaxine versus SSRIs  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 03 Venlafaxine versus SSRIs  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 04 Venlafaxine versus TCAs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 04 Venlafaxine versus TCAs  
 Outcome: 03 Mean endpoint scores



Review: Pharmacology: Venlafaxine  
 Comparison: 04 Venlafaxine versus TCAs  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 04 Venlafaxine versus TCAs  
 Outcome: 05 Leaving the study early due to side effects







Review: Pharmacology: Venlafaxine  
 Comparison: 04 Venlafaxine versus TCAs  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 05 Venlafaxine versus other antidepressants in inpatients  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 05 Venlafaxine versus other antidepressants in inpatients  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 05 Venlafaxine versus other antidepressants in inpatients  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 05 Venlafaxine versus other antidepressants in inpatients  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 05 Venlafaxine versus other antidepressants in inpatients  
 Outcome: 05 Leaving the study early due to side effects



Review: Pharmacology: Venlafaxine  
 Comparison: 05 Venlafaxine versus other antidepressants in inpatients  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 06 Venlafaxine versus other antidepressants in outpatients  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score







Review: Pharmacology: Venlafaxine  
 Comparison: 06 Venlafaxine versus other antidepressants in outpatients  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 06 Venlafaxine versus other antidepressants in outpatients  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 06 Venlafaxine versus other antidepressants in outpatients  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 06 Venlafaxine versus other antidepressants in outpatients  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 06 Venlafaxine versus other antidepressants in outpatients  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 07 Venlafaxine versus other antidepressants in primary care patients  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score



Review: Pharmacology: Venlafaxine  
 Comparison: 07 Venlafaxine versus other antidepressants in primary care patients  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 07 Venlafaxine versus other antidepressants in primary care patients  
 Outcome: 03 Mean endpoint scores







Review: Pharmacology: Venlafaxine  
 Comparison: 07 Venlafaxine versus other antidepressants in primary care patients  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 07 Venlafaxine versus other antidepressants in primary care patients  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 07 Venlafaxine versus other antidepressants in primary care patients  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 08 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in inpatients  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 08 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in inpatients  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 08 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in inpatients  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 08 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in inpatients  
 Outcome: 04 Leaving the study early



Review: Pharmacology: Venlafaxine  
 Comparison: 08 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in inpatients  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 08 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in inpatients  
 Outcome: 06 Patients reporting side effects







Review: Pharmacology: Venlafaxine  
 Comparison: 09 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in outpatients  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 09 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in outpatients  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 09 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in outpatients  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 09 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in outpatients  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 09 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in outpatients  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 09 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in outpatients  
 Outcome: 06 Patients reporting side effects



Review: Pharmacology: Venlafaxine  
 Comparison: 10 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in primary care patients  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 10 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in primary care patients  
 Outcome: 02 Number of people not achieving remission







Review: Pharmacology: Venlafaxine  
 Comparison: 10 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in primary care patients  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 10 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in primary care patients  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 10 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in primary care patients  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 10 Venlafaxine versus TCAs and SSRIs (not mirtazapine) in primary care patients  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 11 Venlafaxine versus SSRIs in inpatients  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 11 Venlafaxine versus SSRIs in inpatients  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 11 Venlafaxine versus SSRIs in inpatients  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 11 Venlafaxine versus SSRIs in inpatients  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 11 Venlafaxine versus SSRIs in inpatients  
 Outcome: 05 Leaving the study early due to side effects



Review: Pharmacology: Venlafaxine  
 Comparison: 11 Venlafaxine versus SSRIs in inpatients  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 12 Venlafaxine versus SSRIs in outpatients  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score







Review: Pharmacology: Venlafaxine  
 Comparison: 12 Venlafaxine versus SSRIs in outpatients  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 12 Venlafaxine versus SSRIs in outpatients  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 12 Venlafaxine versus SSRIs in outpatients  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 12 Venlafaxine versus SSRIs in outpatients  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 12 Venlafaxine versus SSRIs in outpatients  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 13 Venlafaxine versus SSRIs in primary care patients  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score



Review: Pharmacology: Venlafaxine  
 Comparison: 13 Venlafaxine versus SSRIs in primary care patients  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 13 Venlafaxine versus SSRIs in primary care patients  
 Outcome: 03 Mean endpoint scores







Review: Pharmacology: Venlafaxine  
 Comparison: 13 Venlafaxine versus SSRIs in primary care patients  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 13 Venlafaxine versus SSRIs in primary care patients  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 13 Venlafaxine versus SSRIs in primary care patients  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 14 Venlafaxine versus TCAs in inpatients  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 14 Venlafaxine versus TCAs in inpatients  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 14 Venlafaxine versus TCAs in inpatients  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 14 Venlafaxine versus TCAs in inpatients  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 14 Venlafaxine versus TCAs in inpatients  
 Outcome: 06 Patients reporting side effects



Review: Pharmacology: Venlafaxine  
 Comparison: 15 Venlafaxine versus TCAs in outpatients  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 15 Venlafaxine versus TCAs in outpatients  
 Outcome: 03 Mean endpoint scores







Review: Pharmacology: Venlafaxine  
 Comparison: 15 Venlafaxine versus TCAs in outpatients  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 15 Venlafaxine versus TCAs in outpatients  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 15 Venlafaxine versus TCAs in outpatients  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 16 Venlafaxine versus TCAs in primary care patients  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 16 Venlafaxine versus TCAs in primary care patients  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 16 Venlafaxine versus TCAs in primary care patients  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 16 Venlafaxine versus TCAs in primary care patients  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 16 Venlafaxine versus TCAs in primary care patients  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 17 Venlafaxine (75 mg) versus SSRIs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score



Review: Pharmacology: Venlafaxine  
 Comparison: 17 Venlafaxine (75 mg) versus SSRIs  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 17 Venlafaxine (75 mg) versus SSRIs  
 Outcome: 03 Mean endpoint scores







Review: Pharmacology: Venlafaxine  
 Comparison: 17 Venlafaxine (75 mg) versus SSRIs  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 17 Venlafaxine (75 mg) versus SSRIs  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 17 Venlafaxine (75 mg) versus SSRIs  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 18 Venlafaxine (<= 150 mg) versus other antidepressants  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 18 Venlafaxine (<=150 mg) versus other antidepressants  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 18 Venlafaxine (<=150 mg) versus other antidepressants  
 Outcome: 03 Mean endpoint scores



Review: Pharmacology: Venlafaxine  
 Comparison: 18 Venlafaxine (<=150 mg) versus other antidepressants  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 18 Venlafaxine (<= 150 mg) versus other antidepressants  
 Outcome: 05 Leaving the study early due to side effects







Review: Pharmacology: Venlafaxine  
 Comparison: 18 Venlafaxine (<=150 mg) versus other antidepressants  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 19 Venlafaxine (<=150 mg) versus SSRIs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 19 Venlafaxine (<=150 mg) versus SSRIs  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 19 Venlafaxine (<=150 mg) versus SSRIs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 19 Venlafaxine (<=150 mg) versus SSRIs  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 19 Venlafaxine (<=150 mg) versus SSRIs  
 Outcome: 05 Leaving the study early due to side effects



Review: Pharmacology: Venlafaxine  
 Comparison: 19 Venlafaxine (<=150 mg) versus SSRIs  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 20 Venlafaxine (<= 150 mg) versus TCAs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score







Review: Pharmacology: Venlafaxine  
 Comparison: 20 Venlafaxine (<=150 mg) versus TCAs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 20 Venlafaxine (<= 150 mg) versus TCAs  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 20 Venlafaxine (<=150 mg) versus TCAs  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 20 Venlafaxine (<=150 mg) versus TCAs  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 21 Venlafaxine (>= 150 mg) versus other antidepressants  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 21 Venlafaxine (>=150 mg) versus other antidepressants  
 Outcome: 02 Number of people not achieving remission



Review: Pharmacology: Venlafaxine  
 Comparison: 21 Venlafaxine (>=150 mg) versus other antidepressants  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 21 Venlafaxine (>=150 mg) versus other antidepressants  
 Outcome: 04 Leaving the study early







Review: Pharmacology: Venlafaxine  
 Comparison: 21 Venlafaxine (>= 150 mg) versus other antidepressants  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 21 Venlafaxine (>=150 mg) versus other antidepressants  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 22 Venlafaxine (>= 150 mg) versus TCAs and SSRIs (not mirtazapine)  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 22 Venlafaxine (>= 150 mg) versus TCAs and SSRIs (not mirtazapine)  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 22 Venlafaxine (>=150 mg) versus TCAs and SSRIs (not mirtazapine)  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 22 Venlafaxine (>=150 mg) versus TCAs and SSRIs (not mirtazapine)  
 Outcome: 04 Leaving the study early



Review: Pharmacology: Venlafaxine  
 Comparison: 22 Venlafaxine (>=150 mg) versus TCAs and SSRIs (not mirtazapine)  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 22 Venlafaxine (>=150 mg) versus TCAs and SSRIs (not mirtazapine)  
 Outcome: 06 Patients reporting side effects







Review: Pharmacology: Venlafaxine  
 Comparison: 23 Venlafaxine (>=150 mg) versus SSRIs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 23 Venlafaxine (>=150 mg) versus SSRIs  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 23 Venlafaxine (>=150 mg) versus SSRIs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 23 Venlafaxine (>=150 mg) versus SSRIs  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 23 Venlafaxine (>=150 mg) versus SSRIs  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 23 Venlafaxine (>=150 mg) versus SSRIs  
 Outcome: 06 Patients reporting side effects



Review: Pharmacology: Venlafaxine  
 Comparison: 24 Venlafaxine (>=150 mg) versus TCAs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 24 Venlafaxine (>150mg) versus other antidepressants  
 Outcome: 02 Number of people not achieving remission







Review: Pharmacology: Venlafaxine  
 Comparison: 24 Venlafaxine (>=150 mg) versus TCAs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 24 Venlafaxine (>=150 mg) versus TCAs  
 Outcome: 04 Leaving the study early




Review: Pharmacology: Venlafaxine  
 Comparison: 24 Venlafaxine (>=150 mg) versus TCAs  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 24 Venlafaxine (>=150 mg) versus TCAs  
 Outcome: 06 Patients reporting side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 25 Venlafaxine (>150 mg) versus other antidepressants  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 25 Venlafaxine (>150 mg) versus other antidepressants  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 25 Venlafaxine (>150 mg) versus other antidepressants  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 25 Venlafaxine (> 150 mg) versus other antidepressants  
 Outcome: 04 Leaving the study early



Review: Pharmacology: Venlafaxine  
 Comparison: 25 Venlafaxine (>150 mg) versus other antidepressants  
 Outcome: 05 Leaving the study early due to side effects




Review: Pharmacology: Venlafaxine  
 Comparison: 25 Venlafaxine (> 150 mg) versus other antidepressants  
 Outcome: 06 Patients reporting side effects







Review: Pharmacology: Venlafaxine  
 Comparison: 26 Venlafaxine (>150 mg) versus SSRIs  
 Outcome: 01 Number of people not achieving at least 50% reduction in depression score




Review: Pharmacology: Venlafaxine  
 Comparison: 26 Venlafaxine (> 150 mg) versus SSRIs  
 Outcome: 02 Number of people not achieving remission




Review: Pharmacology: Venlafaxine  
 Comparison: 26 Venlafaxine (>150 mg) versus SSRIs  
 Outcome: 03 Mean endpoint scores




Review: Pharmacology: Venlafaxine  
 Comparison: 26 Venlafaxine (>150 mg) versus SSRIs  
 Outcome: 04 Leaving the study early



Review: Pharmacology: Venlafaxine  
 Comparison: 26 Venlafaxine (>150 mg) versus SSRIs  
 Outcome: 05 Leaving the study early due to side effects



Review: Pharmacology: Venlafaxine  
 Comparison: 26 Venlafaxine (>150 mg) versus SSRIs  
 Outcome: 06 Patients reporting side effects




# Treatments for depression with a seasonal pattern/seasonal affective disorder (SAD)

## SAD.01. Treatments for SAD – bright light versus waitlist control


### SAD.01.01. Number leaving the study early for any reason

Review: Depression update pharmacology; treatments for SAD  
 Comparison: 01 Bright light vs waitlist control  
 Outcome: 01 Leaving study early for any reason




**SAD.01.02. Number leaving the study early due to side effects**

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 01 Bright light vs waitlist control  
 Outcome: 02 Leaving study early due to side effects



**SAD.01.03. Mean endpoint SAD depression scores (SIGH-SAD-SR) (self-rated)**


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 01 Bright light vs waitlist control  
 Outcome: 03 Mean self rated SAD depression scores (SIGH-SAD-SR) at endpoint






### SAD.01.04. Mean endpoint SAD depression scores (SIGH-SAD) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 01 Bright light vs waitlist control  
 Outcome: 04 Mean clinician rated SAD depression scores (SIGH-SAD) at endpoint




### SAD.01.05. Mean endpoint depression scores (HRSD-21) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 01 Bright light vs waitlist control  
 Outcome: 05 Mean clinician rated typical depression scores (HRSD-21) at endpoint




### SAD.01.06. Mean depression scores at endpoint (self-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 01 Bright light vs waitlist control  
 Outcome: 06 Mean self rated depression scores at endpoint




### SAD.01.07. Mean endpoint atypical depression scores (SAD subscale) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 01 Bright light vs waitlist control  
 Outcome: 07 Mean clinician rated atypical depression scores (SADsubscale) at endpoint




**SAD.01.08. Mean endpoint atypical depression scores (SAD-SR subscale) (self-rated)**

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 01 Bright light vs waitlist control  
 Outcome: 08 Mean self rated atypical depression scores (SAD-SR subscale) at endpoint




### SAD.01.10. Non-response data (SIGH-SAD)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 01 Bright light vs waitlist control  
 Outcome: 10 Non remission (SIGH-SAD-SR)



### SAD.01.11. Non-response data (SIGN-SAD)


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 01 Bright light vs waitlist control  
 Outcome: 11 Non response (SIGH-SAD)



## SAD.02. Treatments for SAD – bright light versus attentional control


### SAD.02.01. Number leaving study early for any reason

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 02 Bright light vs attentional control  
 Outcome: 01 Leaving study early for any reason




### SAD.02.02. Number leaving study early due to lack of efficacy

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 02 Bright light vs attentional control  
 Outcome: 02 Leaving study early due to lack of efficacy




### SAD.02.03. Number of reported side effects

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 02 Bright light vs attentional control  
 Outcome: 03 Reported side effects



### SAD.02.04. Mean endpoint depression scores (SIGH-SAD) (clinician-rated)

Review: Depression update pharmacology; treatments for SAD  
 Comparison: 02 Bright light vs attentional control  
 Outcome: 04 Mean clinician rated SAD depression scores (SIGH-SAD) at endpoint




### SAD.02.05. Mean endpoint typical depression scores (HAM-D17/HRSD-21) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD

Comparison: 02 Bright light vs attentional control


Outcome: 05 Mean clinician rated typical depression scores (HAM-D17/HRSD-21) at endpoint






### SAD.02.06. Mean endpoint atypical depression scores (SAD subscale) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 02 Bright light vs attentional control  
 Outcome: 06 Mean clinician rated atypical depression scores (SAD subscale) at endpoint




### SAD.02.07. Mean endpoint depression scores (BDI) (self-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 02 Bright light vs attentional control  
 Outcome: 07 Mean self rated depression scores (BDI) at endpoint




### SAD.02.08. Non-remission data (SIGH-SAD, SIGH-SAD-SR or HDRS)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 02 Bright light vs attentional control  
 Outcome: 08 Non remission (SIGH-SAD or SIGH-SAD-SR or HDRS)



### SAD.02.09. Non-response data (SIGH-SAD)


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 02 Bright light vs attentional control  
 Outcome: 09 Non response (SIGH-SAD)



### SAD.03. Treatments for SAD – bright light versus active treatment control


#### SAD.03.01. Number leaving study early for any reason

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 03 Bright light vs active treatment control  
 Outcome: 01 Leaving study early for any reason




### SAD.03.02. Number leaving study early due to side effects

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 03 Bright light vs active treatment control  
 Outcome: 02 Leaving study early due to side effects




### SAD.03.03. Number leaving study early due to lack of efficacy

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 03 Bright light vs active treatment control  
 Outcome: 03 Leaving study early due to lack of efficacy




### SAD.03.04. Number of reported side effects

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 03 Bright light vs active treatment control  
 Outcome: 04 Reported side effects




### SAD.03.05. Mean SAD depression endpoint scores (SIGH-SAD) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 03 Bright light vs active treatment control  
 Outcome: 05 Mean clinician rated SAD depression scores (SIGH-SAD) at endpoint




**SAD.03.06. Mean atypical depression endpoint scores (HAM-D17/HRSD-21) (clinician-rated)**

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 03 Bright light vs active treatment control  
 Outcome: 06 Mean clinician rated typical depression scores (HAM-D17/HRSD-21) at endpoint



**SAD.03.07. Mean atypical depression endpoint scores (SAD subscale) (clinician-rated)**


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 03 Bright light vs active treatment control  
 Outcome: 07 Mean clinician rated atypical depression scores (SADsubscale) at endpoint






### SAD.03.08. Mean depression endpoint scores (BDI) (self-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 03 Bright light vs active treatment control  
 Outcome: 08 Mean self rated depression scores (BDI) at endpoint




### SAD.03.09. Non-remission data

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 03 Bright light vs active treatment control  
 Outcome: 09 Non remission



### SAD.03.10. Non-response data


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 03 Bright light vs active treatment control  
 Outcome: 10 Non response



### SAD.04. Treatments for SAD - bright light versus light + CBT combination


#### SAD.04.01. Number leaving study early for any reason

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 04 Bright light vs light + CBT combo  
 Outcome: 01 Leaving study early for any reason




### SAD.04.02. Number leaving study early due to side effects

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 04 Bright light vs light + CBT combo  
 Outcome: 02 Leaving study early due to side effects




### SAD.04.03. Mean SAD depression endpoint scores (SIGH-SAD) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 04 Bright light vs light + CBT combo  
 Outcome: 03 Mean clinician rated SAD depression scores (SIGH-SAD) at endpoint




### SAD.04.04. Mean typical depression endpoint scores (HAM-D17/HRSD-21) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 04 Bright light vs light + CBT combo  
 Outcome: 04 Mean clinician rated typical depression scores (HAMD-17/HRSD-21) at endpoint




#### SAD.04.05. Mean atypical depression endpoint scores (SAD subscale) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 04 Bright light vs light + CBT combo  
 Outcome: 05 Mean clinician rated atypical depression scores (SADsubscale) at endpoint




#### SAD.04.06. Mean depression endpoint scores (BDI) (self-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 04 Bright light vs light + CBT combo  
 Outcome: 06 Mean self rated depression scores (BDI) at endpoint



**SAD.04.07. Non-remission data (SIGH-SAD)**


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 04 Bright light vs light + CBT combo  
 Outcome: 07 Non remission (SIGH-SAD)



## SAD.05. Treatments for SAD - morning versus afternoon/evening bright light box


### SAD.05.01. Number leaving study early for any reason

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 05 Morning vs afternoon/evening bright light box  
 Outcome: 01 Leaving study early for any reason




### SAD.05.02. Number leaving study early due to side effects

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 05 Morning vs afternoon/evening bright light box  
 Outcome: 02 Leaving study early due to side effects




### SAD.05.03. Number of reported side effects

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 05 Morning vs afternoon/evening bright light box  
 Outcome: 03 Reported side effects




### SAD.05.04. Mean SAD depression endpoint scores (SIGH-SAD) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 05 Morning vs afternoon/evening bright light box  
 Outcome: 04 Mean clinician rated SAD depression scores (SIGH-SAD) at endpoint



### SAD.05.05. Mean typical depression endpoint scores (HAM-D17/HRSD-31) (clinician-rated)


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 05 Morning vs afternoon/evening bright light box  
 Outcome: 05 Mean clinician rated typical depression scores (HAM-D17/HRSD-31) at endpoint






### SAD.05.06. Mean atypical depression endpoint scores (SAD subscale) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 05 Morning vs afternoon/evening bright light box  
 Outcome: 06 Mean clinician rated atypical depression scores (SAD-subscale) at endpoint




### SAD.05.07. Mean depression endpoint scores (BDI) (self-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 05 Morning vs afternoon/evening bright light box  
 Outcome: 07 Mean self rated depression scores (BDI) at endpoint




### SAD.05.08. Non-remission data

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 05 Morning vs afternoon/evening bright light box  
 Outcome: 08 Non remission



### SAD.05.09. Non-response data


Review: Depression update pharmacology; treatments for SAD  
 Comparison: 05 Morning vs afternoon/evening bright light box  
 Outcome: 09 Non response



## SAD.06. Treatments for SAD – dawn simulation versus attentional control


### SAD.06.01. Number leaving study early for any reason

Review: Depression update pharmacology; treatments for SAD  
 Comparison: 06 Dawn simulation vs attentional control  
 Outcome: 01 Leaving study early for any reason




**SAD.06.02. Number leaving study early due to side effects**

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 06 Dawn simulation vs attentional control  
 Outcome: 02 Leaving study early due to side effects




### SAD.06.03. Number leaving study early due to lack of efficacy

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 06 Dawn simulation vs attentional control  
 Outcome: 03 Leaving study early due to lack of efficacy




### SAD.06.04. Number of reported side effects

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 06 Dawn simulation vs attentional control  
 Outcome: 04 Reported side effects




### SAD.06.05. Mean typical depression endpoint scores (HAM-D17/HRSD-21) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 06 Dawn simulation vs attentional control  
 Outcome: 05 Mean clinician rated typical depression scores (HAMD-17/HRSD-21) at endpoint




### SAD.06.06. Mean atypical depression endpoint scores (SAD subscale) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 06 Dawn simulation vs attentional control  
 Outcome: 06 Mean clinician rated atypical depression scores (SAD-subscale) at endpoint




### SAD.06.07. Non-remission data (SIGH-SAD)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 06 Dawn simulation vs attentional control  
 Outcome: 07 Non remission (SIGH-SAD)



### SAD.06.08. Non-response data (SIGH-SAD)


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 06 Dawn simulation vs attentional control  
 Outcome: 08 Non response (SIGH-SAD)



## SAD.07. Treatments for SAD – bright light versus dawn simulation


### SAD.07.01. Number leaving study early for any reason

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 07 Bright light box vs dawn simulation  
 Outcome: 01 Leaving study early for any reason



### SAD.07.02. Number leaving study early due to side effects


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 07 Bright light box vs dawn simulation  
 Outcome: 02 Leaving study early due to side effects






### SAD.07.03. Number leaving study early due to lack of efficacy

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 07 Bright light box vs dawn simulation  
 Outcome: 03 Leaving study early due to lack of efficacy




### SAD.07.04. Non-remission data (SIGH-SAD)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 07 Bright light box vs dawn simulation  
 Outcome: 04 Non remission (SIGH-SAD)




### SAD.07.05. Non-response data (SIGH-SAD)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 07 Bright light box vs dawn simulation  
 Outcome: 05 Non response (SIGH-SAD)




### SAD.07.06. Mean depression endpoint scores

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 07 Bright light box vs dawn simulation  
 Outcome: 06 Depression: mean endpoint scores



### SAD.07.07. Mean SAD depression endpoint scores


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 07 Bright light box vs dawn simulation  
 Outcome: 07 SAD: mean endpoint scores



## SAD.08. Treatments for SAD - bright light - prevention of new episode


### SAD.08.01. Number leaving study early for any reason

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 08 Bright light: prevention of new episode  
 Outcome: 01 Leaving study early for any reason



### SAD.08.02. Number who relapsed during course of study (BDI $\geq$ 13 for 2 consecutive weeks)


Review: Depression update pharmacology; treatments for SAD  
 Comparison: 08 Bright light: prevention of new episode  
 Outcome: 02 Relapse during course of study (BDI>=13 for 2 consecutive weeks)



**SAD.09. Treatments for SAD – acute-phase treatment – antidepressants versus placebo (efficacy data)**


**SAD.09.01. Non-response data (SIGH-SAD)**

Review: Depression update pharmacology; treatments for SAD  
 Comparison: 09 Acute-phase treatment: antidepressants vs placebo - efficacy data  
 Outcome: 01 Number not achieving  $\geq$  50% reduction in SIGH-SAD score at endpoint




### SAD.09.02. Mean endpoint depression scores (SIGH-SAD) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 09 Acute-phase treatment: antidepressants vs placebo - efficacy data  
 Outcome: 02 Mean endpoint (clinician rated) (antidepressants) SIGH-SAD




### SAD.09.03. Mean endpoint depression scores (BDI) (self-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 09 Acute-phase treatment: antidepressants vs placebo - efficacy data  
 Outcome: 03 Mean endpoint (self rated) BDI



### SAD.09.04. Mean change depression scores (SIGH-SAD) (clinician-rated)


Review: Depression update pharmacology; treatments for SAD  
 Comparison: 09 Acute-phase treatment: antidepressants vs placebo - efficacy data  
 Outcome: 04 Mean change (clinician rated) SIGH-SAD



### SAD.10. Treatments for SAD – acute-phase treatment – antidepressants versus placebo (acceptability and tolerability data)


#### SAD.10.01. Number leaving the study early for any reason

Review: Depression update pharmacology; treatments for SAD  
 Comparison: 10 Acute-phase treatment: antidepressants vs placebo - acceptability and tolerability  
 Outcome: 01 Number leaving the study early for any reason



### SAD.10.02. Number leaving the study early due to side effects


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 10 Acute-phase treatment: antidepressants vs placebo - acceptability and tolerability  
 Outcome: 02 Number leaving the study early due to side effects





### SAD.10.03. Number reporting side effects


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 10 Acute-phase treatment: antidepressants vs placebo - acceptability and tolerability  
 Outcome: 03 Number reporting side effects



### SAD.11. Treatments for SAD - acute-phase treatment - antidepressants versus active control (efficacy data)

#### SAD.11.01. Mean endpoint depression data (SIGH-SAD) (clinician-rated)


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 11 Acute-phase treatment: antidepressants vs active control - efficacy data  
 Outcome: 01 Mean endpoint (clinician rated) SIGH-SAD



### SAD.12. Treatments for SAD – overall efficacy (other interventions)

#### SAD.12.01. Non-response data (SIGH-SAD)


Review: Depression update pharmacology: treatments for SAD  
 Comparison: 12 Overall efficacy (other interventions)  
 Outcome: 01 Number not achieving => 50% reduction in outcome score at endpoint SIGH-SAD



### SAD.13. Treatments for SAD – continuation treatment


#### SAD.13.01. Mean endpoint depression scores (HAM-D21) (clinician-rated)

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 13 Continuation treatment  
 Outcome: 01 Mean endpoint (clinician-rated) HAM-D-21



### SAD.13.02. Number leaving the study early for any reason

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 13 Continuation treatment  
 Outcome: 02 Number leaving the study early for any reason



### SAD.14. Treatments for SAD - antidepressants - prevention of a new episode

#### SAD.14.01. Number of patients experiencing a recurrence

Review: Depression update pharmacology: treatments for SAD  
 Comparison: 14 Antidepressants: prevention of new episode  
 Outcome: 01 Buspirone vs placebo

